CUMULATIVE SUPPLEMENT 7
JUL'99



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGMENT AND SERVICES

1999

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Cumulative Supplement 7

JULY 1999

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

CUMULATIVE SUPPLEMENT 7
JULY 1999

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 19th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 19th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 20th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)

NO APPLICANT NAME CHANGES – JULY 1999

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 19th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $78.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 19th annual edition of the 1998 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/19bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at
http://www.fda.gov/cder/orange/supplement/patents.pdf.

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1998) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1998	MAR 1999	JUN 1999	SEP 1999
DRUG PRODUCTS LISTED	9923	9975	10009	
SINGLE SOURCE	2504 (25.2%)	2520 (25.3%)	2523 (25.2%)	
MULTISOURCE	7308 (73.6%)	7344 (73.6%)	7375 (73.7%)	
THERAPEUTICALLY EQUIVALENT	6934 (69.9%)	6969 (69.9%)	7012 (70.1%)	
NOT THERAPEUTICALLY EQUIVALENT	374 (3.8%)	375 (3.8%)	363 (3.6%)	
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	111 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	10	3	5	
NUMBER OF APPLICANTS	563	570	568	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODONE BITARTRATE			
	+ MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

	ALLAY			
AA	NORTON HN	500MG;5MG	N89907 001	JAN 13, 1989
AA	ZENITH GOLDLINE	500MG;5MG	N89907 001	JAN 13, 1989
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	MALLINCKRODT	500MG;5MG	N88956 001	JUL 19, 1985
	ZYDONE			
AA	MALLINCKRODT	500MG;5MG	N88956 001	JUL 19, 1985

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	OXYCODONE AND ACETAMINOPHEN			
AA	DURAMED	500MG;5MG	N40289 001	MAR 16, 1999

TABLET; ORAL

	OXYCODONE AND ACETAMINOPHEN			
AA	AMIDE PHARM	325MG;5MG	N40203 001	MAR 15, 1999
	PERCOCET			
>DLT<		325MG;2.5MG	N40330 001	JUN 25, 1999
>DLT< AA	ENDO PHARMS	325MG;5MG	N40330 002	JUN 25, 1999
>ADD<	+	325MG;2.5MG	N40330 001	JUN 25, 1999
>ADD<	+	500MG;7.5MG	N40341 001	JUL 26, 1999
>ADD<	+	650MG;10MG	N40341 002	JUL 26, 1999

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	PROPACET 100			
AB	TEVA	650MG;100MG	N70107 001	JUN 12, 1985
@		650MG;100MG	N70107 001	JUN 12, 1985

ACITRETIN

CAPSULE; ORAL

	SORIATANE			
	HLR	10MG	N19821 001	OCT 28, 1996
+		25MG	N19821 002	OCT 28, 1996
	ROCHE	10MG	N19821 001	OCT 28, 1996
+		25MG	N19821 002	OCT 28, 1996

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR			
AB	STASON	200MG	N75090 001	JAN 26, 1999

TABLET; ORAL

	ACYCLOVIR			
AB	CARLSBAD	400MG	N75382 001	APR 30, 1999
AB		800MG	N75382 002	APR 30, 1999

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

	ACYCLOVIR			
>ADD< AP	ABBOTT	EQ 50MG BASE/ML	N75114 001	JUL 26, 1999
	ACYCLOVIR SODIUM			
AP +	AM PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001	MAY 13, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

+	A I PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001 MAY 13, 1998
AP	MERIDIAN MEDCL TECHN	EQ 50MG BASE/ML	N75065 001 FEB 25, 1999

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL

AB	MEDEVA	0.09MG/INH	N72273 001 AUG 14, 1996
AB	MEDEVA PHARMS MA	0.09MG/INH	N72273 001 AUG 14, 1996

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	HI TECH PHARMA	EQ 0.083% BASE	N75063 001 FEB 09, 1999

SYRUP; ORAL
ALBUTEROL SULFATE

AA	UDL	EQ 2MG BASE/5ML	N75262 001 MAR 30, 1999

ALITRETINOIN

GEL; TOPICAL
PANRETIN

+	LIGAND	EQ 0.1% BASE	N20886 001 FEB 02, 1999

ALLOPURINOL

TABLET; ORAL
ZYLOPRIM

AB	FARO PHARMS	100MG	N16084 001
AB +		300MG	N16084 002
AB	GLAXO WELLCOME	100MG	N16084 001
AB +		300MG	N16084 002

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION
CERNEVIT-12

+	BAXTER HLTHCARE	11.2 IU/VIAL;125MG/VIAL;60 UGM/VIAL; 200 IU/VIAL;5.5MG/VIAL;414 UGM/VIAL; 46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL; 4.14MG/VIAL;3.51MG/VIAL; 3,500 IU/VIAL	N20924 001 APR 06, 1999

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL

AP	GENSIA SICOR PHARMS	0.5MG/ML	N75196 001 APR 30, 1999

AMCINONIDE

CREAM; TOPICAL
CYCLOCORT

@	FUJISAWA HLTHCARE	0.025%	N18116 001
+		0.1%	N18116 002
	LEDERLE	0.025%	N18116 001
+		0.1%	N18116 002

LOTION; TOPICAL
CYCLOCORT

+	FUJISAWA HLTHCARE	0.1%	N19729 001 JUN 13, 1988
+	LEDERLE	0.1%	N19729 001 JUN 13, 1988

OINTMENT; TOPICAL
CYCLOCORT

+	FUJISAWA HLTHCARE	0.1%	N18498 001
+	WYETH AYERST	0.1%	N18498 001

AMINO ACIDS

INJECTABLE; INJECTION
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

	FRESENIUS KABI	5.2%	N18901 001 APR 06, 1984

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE					
PHARMACIA AND UPJOHN	5.2%	N18901 001 APR 06, 1984			
NEOPHAM 6.4%					
@ FRESENIUS KABI	6.4%	N18792 001 JAN 17, 1984			
@ PHARMACIA AND UPJOHN	6.4%	N18792 001 JAN 17, 1984			
NOVAMINE 11.4%					
FRESENIUS KABI	11.4%	N17957 003 AUG 09, 1982	>_DLT_>		
PHARMACIA AND UPJOHN	11.4%	N17957 003 AUG 09, 1982	>_DLT_> >_ADD_>		
NOVAMINE 15%					
FRESENIUS KABI	15%	N17957 004 NOV 28, 1986	>_DLT_> >_ADD_>		
PHARMACIA AND UPJOHN	15%	N17957 004 NOV 28, 1986			
NOVAMINE 8.5%					
@ FRESENIUS KABI	8.5%	N17957 002 AUG 09, 1982	>_DLT_> >_DLT_>		
@ PHARMACIA AND UPJOHN	8.5%	N17957 002 AUG 09, 1982	>_DLT_> >_DLT_>		

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%					
@ FRESENIUS KABI	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML	N17957 001	>_DLT_> >_DLT_> >_ADD_>		
@ PHARMACIA AND UPJOHN	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML	N17957 001	>_ADD_> >_ADD_> >_ADD_>		

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE						
>_DLT_>	AP	SMITH AND NEPHEW	25MG/ML	N88749 001 MAY 30, 1985	>_ADD_>	
>_DLT_> >_ADD_> >_ADD_>		@	25MG/ML	N88749 001 MAY 30, 1985	>_ADD_> >_ADD_> >_ADD_> >_ADD_> >_ADD_> >_ADD_> >_ADD_> >_ADD_> >_ADD_> >_ADD_>	

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HCL				
AB	ALPHAPHARM	200MG		N75188 001 FEB 24, 1999
AB	NOVOPHARM	200MG		N74895 001 APR 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

AMITRIPTYLINE HCL				
AP	STERIS	10MG/ML		N85594 001
	@	10MG/ML		N85594 001
ELAVIL				
AP	* ZENECA	10MG/ML		N12704 001
	+	10MG/ML		N12704 001

TABLET; ORAL

AMITRIPTYLINE HCL				
BP	COPLEY PHARM	10MG		N88421 001 APR 30, 1984
BP		25MG		N88422 001 APR 30, 1984
BP		50MG		N88423 001 APR 30, 1984
BP		75MG		N88424 001 APR 30, 1984
BP		100MG		N88425 001 APR 30, 1984
BP		150MG		N88426 001 APR 30, 1984
	@	10MG		N88421 001 APR 30, 1984
	@	25MG		N88422 001 APR 30, 1984
	@	50MG		N88423 001 APR 30, 1984
	@	75MG		N88424 001 APR 30, 1984
	@	100MG		N88425 001 APR 30, 1984
	@	150MG		N88426 001 APR 30, 1984
ENDEP				
AB	ROCHE	10MG		N83639 001
AB		25MG		N83639 002

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
ENDEP
AB ROCHE 50MG N83639 003
AB 75MG N83639 004
AB 100MG N83639 005
@ 10MG N83639 001
@ 25MG N83639 002
@ 50MG N83639 003
@ 75MG N83639 004
@ 100MG N83639 005

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN
AB RANBAXY 250MG N65016 001 APR 08, 1999
AB 500MG N65016 002 APR 08, 1999

POWDER FOR RECONSTITUTION; ORAL
AMOXIL
SMITHKLINE BEECHAM 200MG/5ML N50760 001 APR 15, 1999
+ 400MG/5ML N50760 002 APR 15, 1999

TABLET, CHEWABLE; ORAL
AMOXIL
SMITHKLINE BEECHAM 200MG N50761 001 APR 15, 1999
+ 400MG N50761 002 APR 15, 1999

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC
+ ALZA 50MG/VIAL N50729 001 NOV 22, 1996
+ 100MG/VIAL N50729 002 NOV 22, 1996
+ SEQUUS 50MG/VIAL N50729 001 NOV 22, 1996

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC
+ SEQUUS 100MG/VIAL N50729 002 NOV 22, 1996

AMPRENAVIR

CAPSULE; ORAL
AGENERASE
GLAXO WELLCOME 50MG N21007 001 APR 15, 1999
+ 150MG N21007 002 APR 15, 1999

SOLUTION; ORAL
AGENERASE
+ GLAXO WELLCOME 15MG/ML N21039 001 APR 15, 1999

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
KABIVITE PED F + W KIT
+ FRESENIUS KABI N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A N20176 001 DEC 29, 1993
+ PHARMACIA AND UPJOHN N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A N20176 001 DEC 29, 1993

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB	ENDO PHARMS	325MG;50MG;40MG;30MG	N75351 001 MAR 05, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	STEVENS J	385MG;30MG;25MG	N74988 001 APR 30, 1999
AB		770MG;60MG;50MG	N74988 002 APR 30, 1999

> DLT > ASTEMIZOLE

> DLT > TABLET; ORAL
> DLT > HISMANAL
> DLT > + JANSSEN 10MG N19402 001
> DLT > DEC 29, 1988

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	APOTHECON	50MG	N73317 001 MAR 20, 1992
AB		100MG	N73318 001 MAR 20, 1992
	@	50MG	N73317 001 MAR 20, 1992
	@	100MG	N73318 001 MAR 20, 1992

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL W/ ATROPINE SULFATE

AA	ZENITH GOLDLINE	0.025MG;2.5MG	N86727 001
	@	0.025MG;2.5MG	N86727 001

AZATHIOPRINE

TABLET; ORAL
AZATHIOPRINE

AB	APPLIED ANAL	50MG	N75252 001 JUN 07, 1999

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

AT	* ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002
	@	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002
AT	PHARMADERM	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002
	+	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL
CORZIDE

	APOTHECON	5MG;40MG	N18647 001 MAY 25, 1983
	+	5MG;80MG	N18647 002 MAY 25, 1983
	BRISTOL MYERS SQUIBB	5MG;40MG	N18647 001 MAY 25, 1983
	*	5MG;80MG	N18647 002 MAY 25, 1983

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

	* BAYER	60 UMOLAR	N50114 001
	+ HOLLISTER STIER LABS	60 UMOLAR	N50114 001

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE
AB ALTANA EQ 0.05% BASE N75373 001 JUN 22, 1999

BETAMETHASONE VALERATE

AEROSOL; TOPICAL
LUXIQ
+ CONNETICS EQ 0.12% BASE N20934 001 FEB 28, 1999

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN
+ GLAXO WELLCOME 50MG N20358 001 OCT 04, 1996
+ 100MG N20358 002 OCT 04, 1996
+ 150MG N20358 003 OCT 04, 1996

WELLBUTRIN SR
+ GLAXO WELLCOME 50MG N20358 001 OCT 04, 1996
+ 100MG N20358 002 OCT 04, 1996
+ 150MG N20358 003 OCT 04, 1996

BUSULFAN

INJECTABLE; INJECTION
BUSULFEX
+ ORPHAN MEDCL 6MG/ML N20954 001 FEB 04, 1999

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT
+ SYNTEX 2% N19215 001 NOV 25, 1985

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT
@ SYNTEX 2% N19215 001 NOV 25, 1985

FEMSTAT ONE
+ KV PHARM 2% N19881 001 FEB 07, 1997
+ SYNTEX 2% N19881 001 FEB 07, 1997

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
ENDOSOL EXTRA
AT AKORN 0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML N20079 001 NOV 27, 1991
AT ALLERGAN 0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML N20079 001 NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N18271 001
@ 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N18271 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

	ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER			
	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML	N18269 002 JAN 17, 1983	
@		35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML	N18269 002 JAN 17, 1983	

CAPECITABINE

TABLET; ORAL

XELODA			
HLR	150MG	N20896 001 APR 30, 1998	
ROCHE	150MG	N20896 001 APR 30, 1998	

CAPTOPRIL

TABLET; ORAL

	CAPTOPRIL				
AB	BAKER NORTON	12.5MG	N74590 004 AUG 30, 1996	> DLT >	
AB		25MG	N74590 002 AUG 30, 1996	> DLT >	
AB		50MG	N74590 001 AUG 30, 1996	> DLT >	
AB		100MG	N74590 003 AUG 30, 1996	> DLT >	
AB	ZENITH GOLDLINE	12.5MG	N74590 004 AUG 30, 1996	> ADD >	
AB		25MG	N74590 002 AUG 30, 1996	> ADD >	
AB		50MG	N74590 001 AUG 30, 1996	> ADD >	
AB		100MG	N74590 003 AUG 30, 1996	> ADD >	
				> ADD >	
				> DLT >	
				> DLT >	

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN			
+ ROERIG	EQ 1GM BASE/VIAL	N50306 001	
+	EQ 2GM BASE/VIAL	N50306 004	
+	EQ 5GM BASE/VIAL	N50306 002	
+	EQ 10GM BASE/VIAL	N50306 006	
+	EQ 30GM BASE/VIAL	N50306 007	
@	EQ 1GM BASE/VIAL	N50306 001	
@	EQ 2GM BASE/VIAL	N50306 004	
@	EQ 5GM BASE/VIAL	N50306 002	
@	EQ 10GM BASE/VIAL	N50306 006	
@	EQ 30GM BASE/VIAL	N50306 007	

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OCUPRESS			
+ CIBA	1%	N19972 001 MAY 23, 1990	
+ OTSUKA	1%	N19972 001 MAY 23, 1990	

CEFACLOR

CAPSULE; ORAL

CEFACLOR			
LEDERLE	EQ 250MG BASE	N64107 001 APR 27, 1995	
	EQ 500MG BASE	N64107 002 APR 27, 1995	
@	EQ 250MG BASE	N64107 001 APR 27, 1995	
@	EQ 500MG BASE	N64107 002 APR 27, 1995	
TEVA	EQ 250MG BASE	N64081 001 SEP 16, 1996	
	EQ 500MG BASE	N64081 002 SEP 16, 1996	
@	EQ 250MG BASE	N64081 001 SEP 16, 1996	
@	EQ 500MG BASE	N64081 002 SEP 16, 1996	

POWDER FOR RECONSTITUTION; ORAL

CEFACLOR			
LEDERLE	EQ 125MG BASE/5ML	N64114 001 APR 28, 1995	

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL
CEFACLOR

>DLT<	LEDERLE	EQ 187MG BASE/5ML	N64115 001	
>DLT<			APR 28, 1995	
>DLT<		EQ 250MG BASE/5ML	N64116 001	
>DLT<			APR 28, 1995	
>DLT<		EQ 375MG BASE/5ML	N64110 001	
>DLT<			APR 28, 1995	
>ADD<	@	EQ 125MG BASE/5ML	N64114 001	
>ADD<			APR 28, 1995	
>ADD<	@	EQ 187MG BASE/5ML	N64115 001	
>ADD<			APR 28, 1995	
>ADD<	@	EQ 250MG BASE/5ML	N64116 001	
>ADD<			APR 28, 1995	
>ADD<	@	EQ 375MG BASE/5ML	N64110 001	
>ADD<			APR 28, 1995	

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

AB	BARR	EQ 500MG BASE	N65015 001
			JUN 22, 1999

TABLET; ORAL
CEFADROXIL

AB	RANBAXY	EQ 1GM BASE	N65018 001
			APR 23, 1999

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
CEPTAZ

AP	+	GLAXO WELLCOME	1GM/VIAL	N50646 002
				SEP 27, 1990
AP	+		2GM/VIAL	N50646 003
				SEP 27, 1990
AP	+		10GM/VIAL	N50646 004
				SEP 27, 1990
	+		1GM/VIAL	N50646 002
				SEP 27, 1990
	+		2GM/VIAL	N50646 003
				SEP 27, 1990
	+		10GM/VIAL	N50646 004
				SEP 27, 1990

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
PENTACEF

AP		SMITHKLINE BEECHAM	1GM/VIAL	N63322 001
				NOV 07, 1995
AP			1GM/VIAL	N64006 001
				MAR 31, 1992
AP			2GM/VIAL	N63322 002
				NOV 07, 1995
AP			2GM/VIAL	N64006 002
				MAR 31, 1992
AP			10GM/VIAL	N64008 002
				MAR 31, 1992
			6GM/VIAL	N64008 001
				MAR 31, 1992
	@		1GM/VIAL	N63322 001
				NOV 07, 1995
	@		1GM/VIAL	N64006 001
				MAR 31, 1992
	@		2GM/VIAL	N63322 002
				NOV 07, 1995
	@		2GM/VIAL	N64006 002
				MAR 31, 1992
	@		6GM/VIAL	N64008 001
				MAR 31, 1992
	@		10GM/VIAL	N64008 002
				MAR 31, 1992

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL

+	BAYER	0.3MG	N20740 004
			JUN 26, 1997
		0.3MG	N20740 004
			JUN 26, 1997
	+	0.4MG	N20740 005
			MAY 24, 1999

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
A-POXIDE

>DLT<	@ ABBOTT	5MG	N85517 001
>DLT<	@	5MG	N85517 001
>ADD<			

CHLOROTRIANISENE

CAPSULE; ORAL

	CHLOROTRIANISENE			
AA	BANNER PHARMACAPS	12MG	N84652 001	
	@	12MG	N84652 001	
	TACE			
AA	+ HOECHST MARION RSSL	12MG	N08102 004	
	+	12MG	N08102 004	

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	CHLORPROMAZINE HCL			
AA	PHARM ASSOC	100MG/ML	N40224 001	JAN 26, 1999

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	BAKER NORTON	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997
AB	ZENITH GOLDLINE	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997
	CHOLESTYRAMINE LIGHT			
AB	COPLEY PHARM	EQ 4GM RESIN/SCOOPFUL	N74555 002	SEP 30, 1998

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

	CATARASE			
> DLT >	+ CIBA	300 UNITS/VIAL	N16938 001	
> ADD >	@	300 UNITS/VIAL	N16938 001	
	ZOLYSE			
> DLT >	ALCON	750 UNITS/VIAL	N11903 001	
> ADD >	+	750 UNITS/VIAL	N11903 001	

CILOSTAZOL

TABLET; ORAL

	PLETAL			
	OTSUKA	50MG	N20863 001	JAN 15, 1999
	+	100MG	N20863 002	JAN 15, 1999

CISPLATIN

INJECTABLE; INJECTION

> ADD >		CISPLATIN			
> ADD >	AP	AM PHARM PARTNERS	1MG/ML	N74735 001	JUL 16, 1999
> ADD >		PLATINOL-AQ			
> ADD >	AP +	BRISTOL MYERS	1MG/ML	N18057 004	NOV 08, 1988
> ADD >					
> DLT >		+	1MG/ML	N18057 004	NOV 08, 1988
> DLT >					

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

		CLINDAMYCIN PHOSPHATE			
> DLT >	AP	SOLOPAK	EQ 150MG BASE/ML	N62819 001	MAR 15, 1988
> DLT >					
> DLT >	AP		EQ 150MG BASE/ML	N62852 001	MAR 17, 1988
> DLT >					
> ADD >		@	EQ 150MG BASE/ML	N62819 001	MAR 15, 1988
> ADD >					
> ADD >		@	EQ 150MG BASE/ML	N62852 001	MAR 17, 1988
> ADD >					
> DLT >	AP	STERIS	EQ 150MG BASE/ML	N62900 001	JUN 08, 1988
> DLT >					
> DLT >	AP		EQ 150MG BASE/ML	N63079 001	MAR 05, 1990
> DLT >					
> ADD >		@	EQ 150MG BASE/ML	N62900 001	JUN 08, 1988
> ADD >					
> ADD >		@	EQ 150MG BASE/ML	N63079 001	MAR 05, 1990
> ADD >					

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	ALTANA	0.05%	N75430 001	
			MAY 26, 1999	
@		0.05%	N75430 001	
			MAY 26, 1999	

GEL; TOPICAL
CLOBETASOL PROPIONATE

AB	TARO	0.05%	N75279 001	
			MAY 28, 1999	

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

AT	ALTANA	0.05%	N75391 001	
			FEB 08, 1999	

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXAPEN

AB	SMITHKLINE BEECHAM	EQ 250MG BASE	N62233 001	
AB		EQ 500MG BASE	N62233 002	
@		EQ 250MG BASE	N62233 001	
@		EQ 500MG BASE	N62233 002	> DLT >
				> DLT >
				> ADD >
				> ADD >

POWDER FOR RECONSTITUTION; ORAL
CLOXACILLIN SODIUM

AA	TEVA	EQ 125MG BASE/5ML	N62268 001	
+		EQ 125MG BASE/5ML	N62268 001	
	TEGOPEN			
AA	+ APOTHECON	EQ 125MG BASE/5ML	N61453 001	
@		EQ 125MG BASE/5ML	N61453 001	

CLOZAPINE

TABLET; ORAL
CLOZAPINE

AB	CREIGHTON	25MG	N74546 001	
			AUG 30, 1996	
AB		100MG	N74546 002	> ADD >
			AUG 30, 1996	> ADD >
AB	GENEVA PHARMS	25MG	N74546 001	
			AUG 30, 1996	

CLOZAPINE

TABLET; ORAL
CLOZAPINE

AB	GENEVA PHARMS	100MG	N74546 002
			AUG 30, 1996
AB	MYLAN	25MG	N75417 001
			MAY 27, 1999
AB		100MG	N75417 002
			MAY 27, 1999

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLISTIMETHATE

AP	PHARMA TEK	EQ 150MG BASE/VIAL	N64216 001
			FEB 26, 1999

COLY-MYCIN M

AP	+ PARKEDALE	EQ 150MG BASE/VIAL	N50108 002
+		EQ 150MG BASE/VIAL	N50108 002

CORTICOTROPIN

INJECTABLE; INJECTION
CORTICOTROPIN

AP	+ STERIS	40 UNITS/VIAL	N88772 001
			NOV 21, 1984
@		40 UNITS/VIAL	N88772 001
			NOV 21, 1984

CROMOLYN SODIUM

CAPSULE; ORAL
GASTROCROM

+	MEDEVA	100MG	N19188 001
			DEC 22, 1989
@		100MG	N19188 001
			DEC 22, 1989

SOLUTION; INHALATION
CROMOLYN SODIUM

AN	ALPHARMA	10MG/ML	N75067 001
			JUL 19, 1999

SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

AT	ALCON	4%	N75282 001
			JUN 16, 1999

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC
CROMOPTIC
AT KING PHARMS 4% N75088 001 APR 27, 1999

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION
CYSTEINE HCL
@ FRESENIUS KABI 7.25% N19523 001 OCT 22, 1986
@ PHARMACIA AND UPJOHN 7.25% N19523 001 OCT 22, 1986

CYTARABINE

INJECTABLE, LIPOSOMAL; INJECTION
DEPOCYT
+ DEPOTECH 10MG/ML N21041 001 APR 01, 1999

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE
AP + BEDFORD EQ 20MG BASE/VIAL N64103 001 FEB 03, 1995
+ EQ 20MG BASE/VIAL N64103 001 FEB 03, 1995
DAUNORUBICIN HCL
AP BIGMAR EQ 20MG BASE/VIAL N65000 001 MAY 25, 1999

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP
AB + RHONE POULENC RORER 0.01MG/SPRAY N17922 003 AUG 07, 1996
+ 0.01MG/SPRAY N17922 003 AUG 07, 1996
DESMOPRESSIN ACETATE
AB BAUSCH AND LOMB 0.01MG/SPRAY N74830 001 JAN 25, 1999

DEXAMETHASONE

SUSPENSION/DROPS; OPHTHALMIC
DEXAMETHASONE
AT STERIS 0.1% N89170 001 MAY 09, 1989
@ 0.1% N89170 001 MAY 09, 1989
MAXIDEX
AT + ALCON 0.1% N13422 001
+ 0.1% N13422 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
MAXITROL
AT + ALCON 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50065 002
AT + FALCON PHARMS 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50065 002

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL
AT + ALCON 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N50023 002
AT + FALCON PHARMS 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N50023 002

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DECADRON
AP + MERCK EQ 24MG PHOSPHATE/ML N12071 004
+ EQ 24MG PHOSPHATE/ML N12071 004
DEXAMETHASONE SODIUM PHOSPHATE
AP STERIS EQ 4MG PHOSPHATE/ML N83702 001
AP EQ 24MG PHOSPHATE/ML N85606 001
@ EQ 4MG PHOSPHATE/ML N83702 001
@ EQ 24MG PHOSPHATE/ML N85606 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE
AA ENDO PHARMS 5MG N40299 001 MAY 13, 1999

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>DLT> >ADD>	AP	B BRAUN	2.5GM/100ML;450MG/100ML	N18030 001	
	@		2.5GM/100ML;450MG/100ML	N18030 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML	N18030 005	
	@	5GM/100ML;110MG/100ML	N18030 005	

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;200MG/100ML	N18030 004	
@		5GM/100ML;200MG/100ML	N18030 004	

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;330MG/100ML	N18030 003	
@		5GM/100ML;330MG/100ML	N18030 003	

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;450MG/100ML	N18030 002	
@		5GM/100ML;450MG/100ML	N18030 002	

DIAZEPAM

GEL; RECTAL

DIASTAT

+	ATHENA	2.5MG/0.5ML	N20648 001	JUL 29, 1997
		5MG/ML	N20648 002	JUL 29, 1997
		10MG/2ML	N20648 003	JUL 29, 1997
		15MG/3ML	N20648 004	JUL 29, 1997
+		20MG/4ML	N20648 005	JUL 29, 1997
+	ELAN PHARMS	2.5MG/0.5ML	N20648 001	JUL 29, 1997
		5MG/ML	N20648 002	JUL 29, 1997
		10MG/2ML	N20648 003	JUL 29, 1997
		15MG/3ML	N20648 004	JUL 29, 1997
+		20MG/4ML	N20648 005	JUL 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

>DLT> >DLT>	AP	STERIS	5MG/ML	N70911 001	AUG 28, 1986

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

>DLT> >DLT>	AP	STERIS	5MG/ML	N70930 001	DEC 01, 1986
>ADD> >ADD>	@		5MG/ML	N70911 001	AUG 28, 1986
>ADD> >ADD>	@		5MG/ML	N70930 001	DEC 01, 1986

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

>ADD> >ADD>	AB	MYLAN	50MG	N75463 001	JUL 26, 1999

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

	AB	ALCON	0.1% †	N20809 001	MAY 04, 1998
	AB	FALCON PHARMS	0.1%	N20809 001	MAY 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

	AB	MARTEC	50MG	N74986 001	FEB 26, 1999
	AB		75MG	N74986 002	FEB 26, 1999
	AB	NOVOPHARM	50MG	N74723 001	MAR 30, 1999
>ADD> >ADD>	AB	SIDMAK LABS NJ	50MG	N74432 002	JUL 29, 1999
>ADD> >ADD>	AB		75MG	N74432 003	JUL 29, 1999

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL

DICYCLOMINE HCL

	AB	LANNETT	20MG	N40230 001	FEB 26, 1999

† SEE SECTION 1.3 OF INTRODUCTION

DIFLORASONE DIACETATE

CREAM; TOPICAL

		DIFLORASONE DIACETATE		
AB		TARO	0.05%	N75331 001 MAY 14, 1999

OINTMENT; TOPICAL

		DIFLORASONE DIACETATE		
AB		ALTANA	0.05%	N75374 001 APR 27, 1999
AB		TARO	0.05%	N75331 001 MAY 14, 1999
		PSORCON		
AB	+	PHARMACIA AND UPJOHN	0.05%	N19260 001 AUG 28, 1985
	+		0.05%	N19260 001 AUG 28, 1985

DIFLUNISAL

TABLET; ORAL

			DIFLUNISAL		
> DLT >	AB		PUREPAC PHARM	250MG	N74285 001 MAY 07, 1996
> DLT >				500MG	N74285 002 MAY 07, 1996
> DLT >	AB				
> DLT >					N74285 001
> ADD >		@		250MG	MAY 07, 1996
> ADD >					N74285 002
> ADD >		@		500MG	MAY 07, 1996
> ADD >					

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

			CARDIZEM CD		
AB3	+		CARDERM	120MG	N20062 001 AUG 10, 1992
AB3	+			180MG	N20062 002 DEC 27, 1991
AB3	+			240MG	N20062 003 DEC 27, 1991
AB3	+			300MG	N20062 004 DEC 27, 1991
BC	+			120MG	N20062 001 AUG 10, 1992

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

			CARDIZEM CD		
BC	+		CARDERM	180MG	N20062 002 DEC 27, 1991
BC	+			240MG	N20062 003 DEC 27, 1991
BC	+			300MG	N20062 004 DEC 27, 1991
			CARTIA XT		
AB3			ANDRX PHARMS	120MG	N74752 002 JUL 09, 1998
AB3				180MG	N74752 001 JUL 09, 1998
AB3				240MG	N74752 003 JUL 09, 1998
AB3				300MG	N74752 004 JUL 09, 1998
		@		120MG	N74752 002 JUL 09, 1998
		@		180MG	N74752 001 JUL 09, 1998
		@		240MG	N74752 003 JUL 09, 1998
		@		300MG	N74752 004 JUL 09, 1998

INJECTABLE; INJECTION

		DILTIAZEM HCL		
AP		MERIDIAN MEDCL TECHN	5MG/ML	N75106 001 APR 29, 1999

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

> DLT >			HYDRAMINE		
> DLT >	AA		ALPHARMA	12.5MG/5ML	N80763 002
> ADD >		@		12.5MG/5ML	N80763 002

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		DIPIVEFRIN HCL		
AT		ALCON	0.1%	N73636 001 JUN 30, 1994

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DIPIVEFRIN HCL

AT	FALCON PHARMS	0.1%	N73636 001	JUN 30, 1994

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	PUREPAC PHARM	25MG	N89425 001	JUL 12, 1990
	@	25MG	N89425 001	JUL 12, 1990

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC

	+ LILLY	250MG	N50678 001	JUN 19, 1995
	+ LILLY RES LABS	250MG	N50678 001	JUN 19, 1995

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

>DLT>	AP	SMITH AND NEPHEW	40MG/ML	N70046 001 AUG 29, 1985
>DLT>	AP		80MG/ML	N70047 001 AUG 29, 1985
>ADD>	@		40MG/ML	N70046 001 AUG 29, 1985
>ADD>	@		80MG/ML	N70047 001 AUG 29, 1985

DOXERCALCIFEROL

CAPSULE; ORAL
HECTOROL

	+ BONE CARE	2.5 UGM	N20862 001	JUN 09, 1999

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION
DOXIL

	+ ALZA	2MG/ML	N50718 001	NOV 17, 1995
	+ SEQUUS	2MG/ML	N50718 001	NOV 17, 1995

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

>DLT>	AP	SOLOPAK	2.5MG/ML	N71754 001 SEP 06, 1988
>DLT>	AP		2.5MG/ML	N71755 001 SEP 06, 1988
>ADD>	@		2.5MG/ML	N71754 001 SEP 06, 1988
>ADD>	@		2.5MG/ML	N71755 001 SEP 06, 1988
>DLT>	AP	STERIS	2.5MG/ML	N73520 001 NOV 27, 1991
>DLT>	AP		2.5MG/ML	N73521 001 NOV 27, 1991
>DLT>	AP		2.5MG/ML	N73523 001 NOV 27, 1991
>ADD>	@		2.5MG/ML	N73520 001 NOV 27, 1991
>ADD>	@		2.5MG/ML	N73521 001 NOV 27, 1991
>ADD>	@		2.5MG/ML	N73523 001 NOV 27, 1991

EPINEPHRINE

INJECTABLE; INJECTION
SUS-PHRINE

+	FOREST LABS	5MG/ML	N07942 001

SUS-PHRINE SULFITE-FREE

	FOREST LABS	1.5MG/AMP	N07942 003 FEB 05, 1999
+		5MG/ML	N07942 001

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	CLIMARA				
BX	+ BERLEX LABS	0.025MG/24HR	N20375 004 MAR 05, 1999		
	ESTRADIOL				
AB	MENOREST	0.0375MG/24HR	N20538 001 JUL 31, 1996		
AB		0.05MG/24HR	N20538 003 JUL 31, 1996		
AB		0.075MG/24HR	N20538 002 JUL 31, 1996	> DLT <	
AB		0.1MG/24HR	N20538 004 JUL 31, 1996	> DLT < > DLT < > ADD < > ADD <	
	VIVELLE-DOT				
AB	NOVARTIS	0.0375MG/24HR	N20538 001 JUL 31, 1996		
AB		0.05MG/24HR	N20538 003 JUL 31, 1996		
AB		0.075MG/24HR	N20538 002 JUL 31, 1996		
AB		0.1MG/24HR	N20538 004 JUL 31, 1996		

TABLET; ORAL

	ESTRADIOL				
AB	MYLAN	0.5MG	N40326 001 APR 21, 1999		
AB		1MG	N40326 002 APR 21, 1999		
AB		2MG	N40326 003 APR 21, 1999		

TABLET; VAGINAL

	VAGIFEM				
+	NOVO NORDISK	25 UGM	N20908 001 MAR 26, 1999		

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

	CENESTIN				
	DURAMED	0.9MG	N20992 003 MAR 24, 1999		
		0.625MG	N20992 002 MAR 24, 1999		

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

	CENESTIN				
+	DURAMED	0.9MG	N20992 003 MAR 24, 1999		

ESTRONE

INJECTABLE; INJECTION

	NATURAL ESTROGENIC SUBSTANCE-ESTRONE				
+	STERIS	2MG/ML	N85237 001 NOV 23, 1982		
@		2MG/ML	N85237 001 NOV 23, 1982		

ESTROPIPATE

CREAM; VAGINAL

	OGEN				
+	ABBOTT	1.5MG/GM	N84710 001		
+	PHARMACIA AND UPJOHN	1.5MG/GM	N84710 001		

TABLET; ORAL

	OGEN .625				
AB	ABBOTT	0.75MG	N83220 001		
AB	PHARMACIA AND UPJOHN	0.75MG	N83220 001		
	OGEN 1.25				
AB	ABBOTT	1.5MG	N83220 002		
AB	PHARMACIA AND UPJOHN	1.5MG	N83220 002		
	OGEN 2.5				
AB	+ ABBOTT	3MG	N83220 003		
AB	+ PHARMACIA AND UPJOHN	3MG	N83220 003		
	OGEN 5				
AB	ABBOTT	6MG	N83220 004		
AB	PHARMACIA AND UPJOHN	6MG	N83220 004		

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	LEVLITE				
	BERLEX LABS	0.02MG;0.1MG	N20860 001 JUL 13, 1998		
+		0.02MG;0.1MG	N20860 001 JUL 13, 1998		

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

		BREVICON 21-DAY		
AB		SEARLE	0.035MG;0.5MG	N17566 001
AB		WATSON LABS	0.035MG;0.5MG	N17566 001
		NORINYL 1+35 21-DAY		
AB		SEARLE	0.035MG;1MG	N17565 001
AB		WATSON LABS	0.035MG;1MG	N17565 001
		TRI-NORINYL 21-DAY		
	+	SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 001 APR 13, 1984
	+	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 001 APR 13, 1984

TABLET; ORAL-28

		BREVICON 28-DAY		
AB		SEARLE	0.035MG;0.5MG	N17743 001
AB		WATSON LABS	0.035MG;0.5MG	N17743 001
		NORINYL 1+35 28-DAY		
AB		SEARLE	0.035MG;1MG	N17565 002
AB		WATSON LABS	0.035MG;1MG	N17565 002
		TRI-NORINYL 28-DAY		
		SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 002 APR 13, 1984
		WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 002 APR 13, 1984

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

			LO/OVRAL		
> ADD >	AB	+	WYETH AYERST	0.03MG;0.3MG	N17612 001
> DLT >		+		0.03MG;0.3MG	N17612 001
> ADD >			**LOW-OGESTREL-21**		
> ADD >	AB		SCS	0.03MG;0.3MG	N75288 001 JUL 28, 1999

TABLET; ORAL-28

			LO/OVRAL-28		
> ADD >	AB		WYETH AYERST	0.03MG;0.3MG	N17802 001
> DLT >				0.03MG;0.3MG	N17802 001
> ADD >			**LOW-OGESTREL-28**		
> ADD >	AB		SCS	0.03MG;0.3MG	N75288 002 JUL 28, 1999

ETODOLAC

TABLET; ORAL

		ETODOLAC		
AB		NOVOPHARM	400MG	N74847 001 APR 23, 1999
AB			500MG	N74847 002 APR 23, 1999

ETOPOSIDE

INJECTABLE; INJECTION

			ETOPOSIDE		
> DLT >	AP		STERIS	20MG/ML	N74228 001 OCT 15, 1996
> DLT >					
> ADD >			@	20MG/ML	N74228 001 OCT 15, 1996
> ADD >					
			VEPESID		
	AP	+	BRISTOL	20MG/ML	N18768 001 NOV 10, 1983
	AP	+	BRISTOL MYERS SQUIBB	20MG/ML	N18768 001 NOV 10, 1983

FERRIC SODIUM GLUCONATE

INJECTABLE; INJECTION

		FERRLECIT		
	+	R AND D LABS	62.5MG/5ML	N20955 001 FEB 18, 1999

FLUOCINONIDE

OINTMENT; TOPICAL

		FLUOCINONIDE		
AB		TARO	0.05%	N75008 001 JUN 30, 1999

FLUOROURACIL

INJECTABLE; INJECTION

			FLUOROURACIL		
	AP		BIGMAR	50MG/ML	N40291 001 MAR 24, 1999
> DLT >	AP		SMITH AND NEPHEW	50MG/ML	N88767 001 DEC 28, 1984
> DLT >					

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

> DLT >	AP	SMITH AND NEPHEW	50MG/ML	N89434 001
> DLT >				MAR 26, 1987
> ADD >		@	50MG/ML	N88767 001
> ADD >				DEC 28, 1984
> ADD >		@	50MG/ML	N89434 001
> ADD >				MAR 26, 1987

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL
PROZAC

		LILLY	EQ 10MG BASE	N20974 001
				MAR 09, 1999
		+	EQ 20MG BASE	N20974 002
				MAR 09, 1999
		+	EQ 10MG BASE	N20974 001
				MAR 09, 1999
		@	EQ 20MG BASE	N20974 002
				MAR 09, 1999

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

	AP	ABBOTT	10MG/ML	N75241 001
				MAY 28, 1999
> DLT >	AP	SMITH AND NEPHEW	10MG/ML	N70078 001
> DLT >				FEB 05, 1986
> ADD >		@	10MG/ML	N70078 001
> ADD >				FEB 05, 1986
> DLT >	AP	STERIS	10MG/ML	N70019 001
> DLT >				SEP 22, 1986
> DLT >	AP		10MG/ML	N70604 001
> DLT >				JAN 02, 1987
> ADD >		@	10MG/ML	N70019 001
> ADD >				SEP 22, 1986
> ADD >		@	10MG/ML	N70604 001
> ADD >				JAN 02, 1987

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION
FLAXEDIL

+	DAVIS AND GECK	20MG/ML	N07842 001
+		100MG/ML	N07842 002
@		20MG/ML	N07842 001
@		100MG/ML	N07842 002

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE

+	SOLOPAK	25MG/ML	N19961 002
			JAN 17, 1991
@		25MG/ML	N19961 002
			JAN 17, 1991

GANIRELIX ACETATE

INJECTABLE; INJECTION
ANTAGON

+	ORGANON INC	EQ 250 UGM BASE/0.5ML	N21057 001
			JUL 29, 1999

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	SOLOPAK	EQ 10MG BASE/ML	N62507 001
			JUN 06, 1985
AP		EQ 40MG BASE/ML	N62507 002
			JUN 06, 1985
@		EQ 10MG BASE/ML	N62507 001
			JUN 06, 1985
@		EQ 40MG BASE/ML	N62507 002
			JUN 06, 1985

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

AT	ALCON	EQ 0.3% BASE	N62196 001
AT	FALCON PHARMS	EQ 0.3% BASE	N62196 001

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

AB	MOVA	4.5MG	N74591 003	DEC 22, 1997
		4.5MG	N74591 003	DEC 22, 1997
AB	NOVOPHARM	1.5MG	N74686 001	APR 20, 1999
AB		3MG	N74686 002	APR 20, 1999
AB		4.5MG	N74686 003	APR 20, 1999
AB		6MG	N74686 004	APR 20, 1999

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

> DLT >	AP	STERIS	0.2MG/ML	N86947 001	JUN 24, 1983
> ADD >	@		0.2MG/ML	N86947 001	JUN 24, 1983

TABLET; ORAL
ROBINUL

+	HORIZON PHARM	1MG	N12827 001	
+	ROBINS AH	1MG	N12827 001	

ROBINUL FORTE

+	HORIZON PHARM	2MG	N12827 002	
+	ROBINS AH	2MG	N12827 002	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

> DLT >	AT	STERIS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001	JUN 11, 1987
> ADD >	@		0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001	JUN 11, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75393 001	MAY 11, 1999
AO		EQ 100MG BASE/ML	N75393 002	MAY 11, 1999

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

> DLT >	AP	SOLOPAK	EQ 5MG BASE/ML	N70801 001	DEC 14, 1987
> DLT >	AP		EQ 5MG BASE/ML	N70864 001	DEC 14, 1987
> ADD >	@		EQ 5MG BASE/ML	N70801 001	DEC 14, 1987
> ADD >	@		EQ 5MG BASE/ML	N70864 001	DEC 14, 1987
> DLT >	AP	STERIS	EQ 5MG BASE/ML	N70713 001	MAY 17, 1988
> DLT >	AP		EQ 5MG BASE/ML	N70744 001	MAY 17, 1988
> ADD >	@		EQ 5MG BASE/ML	N70713 001	MAY 17, 1988
> ADD >	@		EQ 5MG BASE/ML	N70744 001	MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

> DLT >	AP	SMITH AND NEPHEW	10 UNITS/ML	N88458 001	JUL 26, 1984
> DLT >	AP		10 UNITS/ML	N88580 001	OCT 25, 1984
> DLT >	AP		100 UNITS/ML	N88460 001	JUL 26, 1984
> DLT >	AP		100 UNITS/ML	N88581 001	OCT 25, 1984
> ADD >	@		10 UNITS/ML	N88458 001	JUL 26, 1984
> ADD >	@		10 UNITS/ML	N88580 001	OCT 25, 1984

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

> ADD >		@ SMITH AND NEPHEW	100 UNITS/ML	N88460 001	
> ADD >				JUL 26, 1984	
> ADD >		@	100 UNITS/ML	N88581 001	
> ADD >				OCT 25, 1984	
> DLT >	AP	SOLOPAK	100 UNITS/ML	N88459 001	
> DLT >				JUL 26, 1984	
> ADD >		@	100 UNITS/ML	N88459 001	
> ADD >				JUL 26, 1984	

HEPARIN SODIUM

> DLT >	AP	SMITH AND NEPHEW	1,000 UNITS/ML	N88239 001	
> DLT >				JUL 26, 1984	
> ADD >		@	1,000 UNITS/ML	N88239 001	
> ADD >				JUL 26, 1984	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

> ADD >	AA	HALSEY	1.5MG/5ML;5MG/5ML	N40285 001	
> ADD >				JUL 19, 1999	

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HCL

> DLT >	AP	+ LUITPOLD	20MG/ML	N40136 001	
> DLT >				JUN 30, 1997	
> ADD >		+	20MG/ML	N40136 001	
> ADD >				JUN 30, 1997	
> DLT >	AP	SOLOPAK	20MG/ML	N88517 001	
> DLT >				AUG 22, 1985	
> ADD >		@	20MG/ML	N88517 001	
> ADD >				AUG 22, 1985	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

		@ SANOFI	12.5MG;75MG	N20758 001	
				SEP 30, 1997	
			12.5MG;150MG	N20758 002	
				SEP 30, 1997	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

		+ SANOFI	12.5MG;300MG	N20758 003	
				AUG 31, 1998	

AVAPRO HCT

		@ SANOFI	12.5MG;75MG	N20758 001	
				SEP 30, 1997	
		+	12.5MG;150MG	N20758 002	
				SEP 30, 1997	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

	AB	DURAMED	25MG;37.5MG	N75052 001	
				JUN 18, 1999	

HYDROCORTISONE

ENEMA; RECTAL

CORTENEMA

	AB	+ SOLVAY	100MG/60ML	N16199 001	
	BR	+	100MG/60ML	N16199 001	

HYDROCORTISONE

	AB	COPLEY PHARM	100MG/60ML	N74171 001	
				MAY 27, 1994	
	BR		100MG/60ML	N74171 001	
				MAY 27, 1994	

LOTION; TOPICAL

HYDROCORTISONE

> ADD >	AT	THAMES	2.5%	N40247 001	
> ADD >				JUL 23, 1999	

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HYDROCORTISONE ACETATE

> ADD >		+ FERNDALE LABS	2.5%	N40259 001	
> ADD >				JUL 29, 1999	
> ADD >					

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

		HYDROCORTISONE SODIUM SUCCINATE			
> DLT >	AP	STERIS	EQ 100MG BASE/VIAL	N84737 002	
> DLT >	AP		EQ 100MG BASE/VIAL	N84738 001	
> DLT >	AP		EQ 250MG BASE/VIAL	N84737 001	
> DLT >	AP		EQ 500MG BASE/VIAL	N84747 001	
> DLT >	AP		EQ 1GM BASE/VIAL	N84748 001	
> ADD >		@	EQ 100MG BASE/VIAL	N84737 002	
> ADD >		@	EQ 100MG BASE/VIAL	N84738 001	
> ADD >		@	EQ 250MG BASE/VIAL	N84737 001	
> ADD >		@	EQ 500MG BASE/VIAL	N84747 001	
> ADD >		@	EQ 1GM BASE/VIAL	N84748 001	

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

		PAREDRINE		
	+	AKORN	1%	N00004 004
	+	PHARMICS	1%	N00004 004

HYDROXYUREA

CAPSULE; ORAL

		HYDROXYUREA		
AB		PAR PHARM	500MG	N75340 001
				FEB 24, 1999

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		HYDROXYZINE HCL		
> DLT >	AP	SOLOPAK	25MG/ML	N87591 001
> DLT >	AP		50MG/ML	N87593 001
> DLT >	AP		50MG/ML	N87595 001
> ADD >		@	25MG/ML	N87591 001
> ADD >		@	50MG/ML	N87593 001
> ADD >		@	50MG/ML	N87595 001

IBUPROFEN

SUSPENSION; ORAL

		MOTRIN		
AB	+	MCNEIL	100MG/5ML	N19842 001
				SEP 19, 1989

IBUPROFEN

SUSPENSION; ORAL

		MOTRIN		
AB	+	MCNEIL CONS	100MG/5ML	N19842 001
				SEP 19, 1989

TABLET; ORAL

		IBUPROFEN		
AB		NORTON HN	400MG	N71145 001
				SEP 23, 1986
AB			600MG	N71146 001
				SEP 23, 1986
AB			800MG	N71769 001
				MAY 08, 1987
AB		ZENITH GOLDLINE	400MG	N71145 001
				SEP 23, 1986
AB			600MG	N71146 001
				SEP 23, 1986
AB			800MG	N71769 001
				MAY 08, 1987
		MOTRIN		
AB		MCNEIL	300MG	N17463 003
AB			400MG	N17463 002
AB			600MG	N17463 004
AB	+		800MG	N17463 005
				MAY 22, 1985
			100MG	N20418 001
				NOV 16, 1994
AB		MCNEIL CONS	300MG	N17463 003
AB			400MG	N17463 002
AB			600MG	N17463 004
AB	+		800MG	N17463 005
				MAY 22, 1985
			100MG	N20418 001
				NOV 16, 1994

TABLET, CHEWABLE; ORAL

		MOTRIN		
		MCNEIL	50MG	N20135 001
				NOV 16, 1994
	+		100MG	N20135 002
				NOV 16, 1994
		MCNEIL CONS	50MG	N20135 001
				NOV 16, 1994
	+		100MG	N20135 002
				NOV 16, 1994

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

		INDOCIN SR			
> ADD >	**AB**	EON	**75MG**	**N74464 001**	
> ADD >				MAY 28, 1998	
> DLT >	**AB**	+ MERCK	**75MG**	**N18185 001**	
> DLT >				FEB 23, 1982	
> ADD >		@	75MG	N18185 001	
> ADD >				FEB 23, 1982	
		INDOMETHACIN			
> DLT >	**AB**		**75MG**	**N74464 001**	
> DLT >				MAY 28, 1998	

> ADD > INSULIN HUMAN

> ADD > INJECTABLE; INJECTION

> ADD >		VELOSULIN BR		
> ADD >		+ NOVO NORDISK	100 UNITS/ML	N21028 001
> ADD >				JUL 19, 1999

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

		IPRATROPIUM BROMIDE		
AN		ALPHARMA	**0.02%**	**N75111 001**
				APR 22, 1999

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

		ISOETHARINE HCL		
AN		INTL MEDICATION	**0.08%**	**N86651 002**
AN			**0.1%**	**N86651 003**
AN	+		0.1%	N86651 003
AN			**0.167%**	**N86651 005**
AN	+		0.167%	N86651 005
AN			**0.25%**	**N86651 007**
AN	+		**0.25%**	**N86651 007**
	+		0.08%	N86651 002
		ISOETHARINE HCL S/F		
AN	+	DEY	**0.08%**	**N89817 001**
				NOV 22, 1988
AN	+		**0.1%**	**N89818 001**
				NOV 22, 1988

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

		ISOETHARINE HCL S/F		
AN	+	DEY	**0.17%**	**N89819 001**
				NOV 22, 1988
AN	+		**0.25%**	**N89820 001**
				NOV 22, 1988
		@	0.08%	N89817 001
				NOV 22, 1988
		@	0.1%	N89818 001
				NOV 22, 1988
		@	0.17%	N89819 001
				NOV 22, 1988
		@	0.25%	N89820 001
				NOV 22, 1988

ISOFLURANE

LIQUID; INHALATION

		FORANE		
AN	+	BAXTER PHARM PROD	**99.9%**	**N17624 001**
AN	+	OHMEDA	**99.9%**	**N17624 001**

ISOSORBIDE DINITRATE

TABLET; ORAL

		SORBITRATE		
AB		ZENECA	**30MG**	**N88124 001**
				AUG 21, 1990
		@	30MG	N88124 001
				AUG 21, 1990

ISOTRETINOIN

CAPSULE; ORAL

		ACCUTANE		
		HLR	10MG	N18662 002
				MAY 07, 1982
			20MG	N18662 004
				MAR 28, 1983
	+		40MG	N18662 003
				MAY 07, 1982
		ROCHE	10MG	N18662 002
				MAY 07, 1982

ISOTRETINOIN

CAPSULE; ORAL

		ACCUTANE		
		ROCHE	20MG	N18662 004 MAR 28, 1983
		+	40MG	N18662 003 MAY 07, 1982

ITRACONAZOLE

INJECTABLE; INJECTION

		SPORANOX		
		+ JANSSEN	10MG/ML	N20966 001 MAR 30, 1999

KANAMYCIN SULFATE

INJECTABLE; INJECTION

		KANAMYCIN SULFATE		
>_DLT_>	AP	SOLOPAK	EQ 75MG BASE/2ML	N62605 003 FEB 26, 1986
>_DLT_>				
>_DLT_>	AP		EQ 500MG BASE/2ML	N62605 001 FEB 26, 1986
>_DLT_>				
>_DLT_>	AP		EQ 1GM BASE/3ML	N62605 002 FEB 26, 1986
>_DLT_>				
>_ADD_>		@	EQ 75MG BASE/2ML	N62605 003 FEB 26, 1986
>_ADD_>				
>_ADD_>		@	EQ 500MG BASE/2ML	N62605 001 FEB 26, 1986
>_ADD_>				
>_ADD_>		@	EQ 1GM BASE/3ML	N62605 002 FEB 26, 1986
>_ADD_>				

KETOCONAZOLE

TABLET; ORAL

		KETOCONAZOLE		
>_ADD_>	AB	APPLIED ANAL	200MG	N75341 001 JUL 27, 1999
>_ADD_>				
	AB	MUTUAL PHARMA	200MG	N75314 001 JUN 15, 1999
	AB	NOVOPHARM	200MG	N74971 001 JUN 15, 1999
	AB	SIDMAK LABS CA	200MG	N75362 001 JUN 15, 1999

KETOCONAZOLE

TABLET; ORAL

		KETOCONAZOLE		
AB		TARO	200MG	N75319 001 JUN 15, 1999
AB		TEVA	200MG	N75273 001 JUN 15, 1999
		NIZORAL		
AB		+ JANSSEN	200MG	N18533 001
		+	200MG	N18533 001

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

		KETOPROFEN		
AB		ANDRX PHARMS	100MG	N75270 002 MAR 24, 1999
AB			150MG	N75270 003 MAR 24, 1999
AB			200MG	N75270 001 MAR 24, 1999
		ORUVAIL		
AB		WYETH AYERST	100MG	N19816 003 FEB 08, 1995
AB			150MG	N19816 002 FEB 08, 1995
			100MG	N19816 003 FEB 08, 1995
			150MG	N19816 002 FEB 08, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

		KETOROLAC TROMETHAMINE		
AP		ABBOTT	15MG/ML	N74993 001 JAN 27, 1999
AP			30MG/ML	N74993 002 JAN 27, 1999
AP		BEDFORD	15MG/ML	N75222 001 APR 26, 1999
AP			30MG/ML	N75222 002 APR 26, 1999
AP			30MG/ML	N75228 001 APR 26, 1999

KETOROLAC TROMETHAMINE

TABLET; ORAL
KETOROLAC TROMETHAMINE

AB	SIDMAK LABS CA	10MG		N75284 001 JUN 23, 1999

> ADD > KETOTIFEN FUMARATE

> ADD > SOLUTION/DROPS; OPHTHALMIC
> ADD > ZADITOR
> ADD > + CIBA EQ 0.025% BASE N21066 001
> ADD > JUL 02, 1999

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
LABETALOL HCL

AP	BEDFORD	5MG/ML		N75303 001 MAY 28, 1999

TABLET; ORAL
LABETALOL HCL

> ADD > AB	MUTUAL PHARM	100MG		N75215 001
> ADD >				JUL 29, 1999
> ADD > AB		200MG		N75215 002
> ADD >				JUL 29, 1999
> ADD > AB		300MG		N75215 003
> ADD >				JUL 29, 1999
	TRANDATE			
AB	FARO PHARMS	100MG		N18716 001 MAY 24, 1985
AB		200MG		N18716 002 AUG 01, 1984
AB		300MG		N18716 003 AUG 01, 1984
@		400MG		N18716 004 AUG 01, 1984
AB	GLAXO WELLCOME	100MG		N18716 001 MAY 24, 1985
AB		200MG		N18716 002 AUG 01, 1984
AB		300MG		N18716 003 AUG 01, 1984
@		400MG		N18716 004 AUG 01, 1984

LAMIVUDINE

SOLUTION; ORAL
EPIVIR-HBV

+	GLAXO WELLCOME	5MG/ML		N21004 001 DEC 08, 1998
+		5MG/ML		N20596 002 DEC 08, 1998

TABLET; ORAL
EPIVIR-HBV

+	GLAXO WELLCOME	100MG		N21003 001 DEC 08, 1998
+		100MG		N20564 002 DEC 08, 1998

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP	+ ABBOTT	EQ 10MG BASE/ML		N40147 001 JUN 25, 1997
AP	+ BEDFORD	EQ 200MG BASE/VIAL		N40056 001 MAY 23, 1995
	LEUCOVORIN CALCIUM PRESERVATIVE FREE			
AP	+ ABBOTT	EQ 10MG BASE/ML		N40147 001 JUN 25, 1997
AP	+ BEDFORD	EQ 200MG BASE/VIAL		N40056 001 MAY 23, 1995
AP	BIGMAR	EQ 10MG BASE/ML		N40286 001 FEB 26, 1999
AP		EQ 200MG BASE/VIAL		N40258 001 FEB 26, 1999
AP	GENSIA SICOR PHARMS	EQ 10MG BASE/ML		N40332 001 JUN 28, 1999

TABLET; ORAL
LEUCOVORIN CALCIUM

AB	INVAMED	EQ 15MG BASE		N75327 001 MAR 24, 1999
	WELLCOVORIN			
AB	GLAXO WELLCOME	EQ 5MG BASE		N18342 001 JUL 08, 1983
AB	+	EQ 25MG BASE		N18342 002 JUL 08, 1983
@		EQ 5MG BASE		N18342 001 JUL 08, 1983

LEUCOVORIN CALCIUM

TABLET; ORAL
WELLCOVORIN
@ GLAXO WELLCOME — EQ 25MG BASE — N18342 002 JUL 08, 1983

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
XOPENEX
+ SEPRACOR — EQ 0.021% BASE — N20837 001 MAR 25, 1999
+ — EQ 0.042% BASE — N20837 002 MAR 25, 1999

LEVONORGESTREL

>ADD< TABLET; ORAL
>ADD< PLAN B
>ADD< + WOMENS CAPITAL — 0.75MG — N21045 001 JUL 28, 1999
>ADD<

LIDOCAINE

FILM, EXTENDED RELEASE; TRANSDERMAL
LIDODERM
+ HIND HLTHCARE — 700MG/12HR — N20612 001 MAR 19, 1999

LIDOCAINE; PRILOCAINE

AEROSOL; TOPICAL
EMLA
+ ASTRA PHARMS — 2.5%;2.5% — N20962 001 FEB 04, 1998

DISC; TOPICAL
EMLA
+ ASTRA PHARMS — 2.5%;2.5% — N20962 001 FEB 04, 1998

LISINOPRIL

TABLET; ORAL
ZESTRIL
ZENECA — 30MG — N19777 006 JAN 20, 1999

LITHIUM CARBONATE

CAPSULE; ORAL
LITHONATE
AB SOLVAY — 300MG — N16782 001
@ — 300MG — N16782 001

TABLET; ORAL
LITHIUM CARBONATE
AB PFIZER — 300MG — N16834 001
AB + — 300MG — N16834 001
LITHOTABS
AB + SOLVAY — 300MG — N16980 001
@ — 300MG — N16980 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
IMODIUM
AB + JANSSEN — 2MG — N17694 001
@ — 2MG — N17690 001
AB + MCNEIL CONS — 2MG — N17694 001
@ — 2MG — N17690 001

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
LOTEMAX
+ PHARMOS — 0.5% — N20841 001 MAR 09, 1998
@ — 0.5% — N20841 001 MAR 09, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

	ISOLYTE S PH 7.4 IN PLASTIC CONTAINER			
	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19006 001	APR 04, 1984
@		30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19006 001	APR 04, 1984

MALATHION

LOTION; TOPICAL

	OVIDE			
@	MEDICIS	0.5%	N18613 001	AUG 02, 1982
+		0.5%	N18613 001	AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 25%			
> DLT > AP	STERIS	12.5GM/50ML	N87460 001	JUN 27, 1983
> DLT >				
> ADD > @		12.5GM/50ML	N87460 001	JUN 27, 1983
> ADD >				

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

	VERMOX				
AB	+	JANSSEN	100MG	N17481 001	
AB	+	MCNEIL CONS	100MG	N17481 001	

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

	CYCRIN			
	ESI	2.5MG	N81239 001	OCT 30, 1992

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

	CYCRIN			
	ESI	5MG	N81240 001	OCT 30, 1992
		10MG	N89386 001	SEP 09, 1987
@		2.5MG	N81239 001	OCT 30, 1992
@		5MG	N81240 001	OCT 30, 1992
@		10MG	N89386 001	SEP 09, 1987

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DEMEROL				
AP	+	ABBOTT	25MG/ML	N05010 007	
AP	+		50MG/ML	N05010 002	
AP	+		75MG/ML	N05010 009	
AP	+		100MG/ML	N05010 003	
AP	+	SANOFI	25MG/ML	N05010 007	
AP	+		50MG/ML	N05010 002	
AP	+		75MG/ML	N05010 009	
AP	+		100MG/ML	N05010 003	
	MEPERIDINE HCL				
AP	+	ABBOTT	10MG/ML	N88432 001	AUG 16, 1984
AP		ASTRA PHARMS	10MG/ML	N81002 001	JUL 30, 1993
AP		INTL MEDICATION	10MG/ML	N81309 001	AUG 30, 1993
AP		MALLINCKRODT	10MG/ML	N40163 001	MAY 12, 1997
AP		STERIS	10MG/ML	N73443 001	MAR 17, 1992
	MEPERIDINE HCL PRESERVATIVE FREE				
AP	+	ABBOTT	10MG/ML	N88432 001	AUG 16, 1984
AP		ASTRA PHARMS	10MG/ML	N81002 001	JUL 30, 1993
AP		FAULDING	10MG/ML	N40305 001	MAR 10, 1999
AP		INTL MEDICATION	10MG/ML	N81309 001	AUG 30, 1993

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL PRESERVATIVE FREE

AP		MALLINCKRODT	10MG/ML	N40163 001 MAY 12, 1997
AP		STERIS	10MG/ML	N73443 001 MAR 17, 1992

SYRUP; ORAL
DEMEROL

AA	+	ABBOTT	50MG/5ML	N05010 005
AA	+	SANOFI	50MG/5ML	N05010 005

TABLET; ORAL
DEMEROL

AA	+	ABBOTT	50MG	N05010 001
AA	+		100MG	N05010 004
AA	+	SANOFI	50MG	N05010 001
AA	+		100MG	N05010 004

MEPERIDINE HCL

AA		AMIDE PHARM	50MG	N40331 001 MAY 28, 1999
AA			100MG	N40331 002 MAY 28, 1999

MERSALYL SODIUM; THEOPHYLLINE

> DLT > INJECTABLE; INJECTION
> DLT > **MERSALYL-THEOPHYLLINE**

> DLT >	+	STERIS	100MG/ML;50MG/ML	N84875 001
> ADD >	@		100MG/ML;50MG/ML	N84875 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

	+	BRISTOL MYERS SQUIBB	500MG	N20357 001 MAR 03, 1995
			625MG	N20357 003 NOV 05, 1998
			750MG	N20357 004 NOV 05, 1998
			500MG	N20357 001 MAR 03, 1995
	@		625MG	N20357 003 NOV 05, 1998

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

	@	BRISTOL MYERS SQUIBB	750MG	N20357 004 NOV 05, 1998

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE

AP		BIGMAR	EQ 25MG BASE/ML	N40263 001 FEB 26, 1999

METHOTREXATE PRESERVATIVE FREE

AP		BIGMAR	EQ 25MG BASE/ML	N40265 001 FEB 26, 1999
AP			EQ 1GM BASE/VIAL	N40266 001 FEB 26, 1999

METHOTREXATE SODIUM

	+	LEDERLE	EQ 1GM BASE/VIAL	N11719 009 APR 07, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+	LEDERLE	EQ 1GM BASE/VIAL	N11719 009 APR 07, 1988

TABLET; ORAL
METHOTREXATE SODIUM

AB		DURAMED	EQ 2.5MG BASE	N40233 001 JUN 17, 1999

METHOTRIMEPRAZINE

INJECTABLE; INJECTION
LEVOPROME

	+	IMMUNEX	20MG/ML	N15865 001
	@		20MG/ML	N15865 001

METHOXSALEN

INJECTABLE; INJECTION
UVADEX

	+	THERAKOS	0.02MG/ML	N20969 001 FEB 25, 1999

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

> DLT >	AP	SMITH AND NEPHEW	50MG/ML	N70841 001 JAN 02, 1987
> ADD >		@	50MG/ML	N70841 001 JAN 02, 1987

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

> DLT >	AP	STERIS	EQ 40MG BASE/VIAL	N86953 001 JUL 22, 1982
> DLT >	AP		EQ 125MG BASE/VIAL	N87030 001 JUL 22, 1982
> DLT >	AP		EQ 500MG BASE/VIAL	N88523 001 JUL 24, 1984
> DLT >	AP		EQ 1GM BASE/VIAL	N88524 001 JUL 24, 1984
> ADD >		@	EQ 40MG BASE/VIAL	N86953 001 JUL 22, 1982
> ADD >		@	EQ 125MG BASE/VIAL	N87030 001 JUL 22, 1982
> ADD >		@	EQ 500MG BASE/VIAL	N88523 001 JUL 24, 1984
> ADD >		@	EQ 1GM BASE/VIAL	N88524 001 JUL 24, 1984

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

> DLT >	AP	SMITH AND NEPHEW	EQ 5MG BASE/ML	N70623 001 MAR 02, 1987
> ADD >		@	EQ 5MG BASE/ML	N70623 001 MAR 02, 1987

METOLAZONE

TABLET; ORAL
ZAROXOLYN

		MEDEVA	2.5MG	N17386 001
	+		2.5MG	N17386 001

METRONIDAZOLE

INJECTABLE; INJECTION
METRONIDAZOLE

> DLT >	AP	STERIS	500MG/100ML	N70170 001 APR 01, 1986
> ADD >		@	500MG/100ML	N70170 001 APR 01, 1986

MICONAZOLE NITRATE

INSERT, CREAM; VAGINAL, TOPICAL
MONISTAT DUAL- PAK

	+	ADVANCED CARE PRODS	1.2GM,2%	N20968 001 JUN 30, 1999

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB		ALPHARMA US PHARM	200MG	N73508 001 NOV 19, 1993
AB		NMC	200MG	N73508 001 NOV 19, 1993

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

	+	DANBURY PHARMA	EQ 75MG BASE	N63065 002 JUN 10, 1999
AB		GLOBAL PHARM	EQ 50MG BASE	N65005 001 MAR 23, 1999
AB			EQ 100MG BASE	N65005 002 MAR 23, 1999

NADOLOL

TABLET; ORAL
CORGARD

AB		APOTHECON	20MG	N18063 005 OCT 28, 1986
AB			40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+		160MG	N18063 004
AB		BRISTOL MYERS SQUIBB	20MG	N18063 005 OCT 28, 1986

NADOLOL

TABLET; ORAL
CORGARD

AB		BRISTOL MYERS SQUIBB	40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+		160MG	N18063 004

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

> DLT >	AP		SMITH AND NEPHEW	0.02MG/ML	N71671 001
> DLT >					NOV 17, 1987
> DLT >	AP			0.4MG/ML	N71681 001
> DLT >					NOV 17, 1987
> ADD >		@		0.02MG/ML	N71671 001
> ADD >					NOV 17, 1987
> ADD >		@		0.4MG/ML	N71681 001
> ADD >					NOV 17, 1987
> DLT >	AP		STERIS	0.4MG/ML	N71339 001
> DLT >					NOV 18, 1987
> ADD >		@		0.4MG/ML	N71339 001
> ADD >					NOV 18, 1987

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

AB	AMIDE PHARM	50MG	N75274 001
			MAY 26, 1999

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

> DLT >	AO	STERIS	50MG/ML	N88554 001
> DLT >				FEB 10, 1986
> ADD >		@	50MG/ML	N88554 001
> ADD >				FEB 10, 1986

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
DURABOLIN

> DLT >	AO	+ ORGANON	25MG/ML	N11891 001
> DLT >	AO	+	50MG/ML	N11891 002
> ADD >		+	25MG/ML	N11891 001
> ADD >		+	50MG/ML	N11891 002
> DLT >		NANDROLONE PHENPROPIONATE		
> DLT >	AO	STERIS	25MG/ML	N86386 001
> DLT >				JUN 17, 1983
> DLT >	AO		50MG/ML	N87488 001
> DLT >				JUN 17, 1983
> ADD >		@	25MG/ML	N86386 001
> ADD >				JUN 17, 1983
> ADD >		@	50MG/ML	N87488 001
> ADD >				JUN 17, 1983

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN

AB	SIDMAK LABS CA	375MG	N75337 001
			MAY 26, 1999
AB		500MG	N75337 002
			MAY 26, 1999

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP

+	ELAN PHARM	11MG/24HR	N19983 001
			JAN 28, 1992
+		22MG/24HR	N19983 002
			JAN 28, 1992
@		11MG/24HR	N19983 001
			JAN 28, 1992
@		22MG/24HR	N19983 002
			JAN 28, 1992

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN

> DLT >	AP	SMITH AND NEPHEW	5MG/ML	N70633 001
> DLT >				JUN 19, 1986

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN
> ADD > @ SMITH AND NEPHEW 5MG/ML N70633 001
> ADD > JUN 19, 1986

OINTMENT; TRANSDERMAL
NITROGLYCERIN
ALTANA 2% N87355 001
JUL 08, 1988
+ 2% N87355 001
JUL 08, 1988

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA PHARMS 10MG N19810 003
OCT 05, 1995
10MG N19810 003
OCT 05, 1995

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ZOFRAN ODT
GLAXO WELLCOME EQ 4MG BASE N20781 001
JAN 27, 1999
+ EQ 8MG BASE N20781 002
JAN 27, 1999

ORLISTAT

CAPSULE; ORAL
XENICAL
+ ROCHE 120MG N20766 001
APR 23, 1999

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE
AB KIEL 100MG N40249 001
JAN 29, 1999

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
AA MIKART 5MG/5ML N75039 001
JAN 29, 1999

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL
+ ALZA 15MG N20897 003
JUN 22, 1999

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL
TERRAMYCIN
+ PFIZER EQ 125MG BASE/5ML N60595 001
@ EQ 125MG BASE/5ML N60595 001

OXYTETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
TERRAMYCIN
+ PFIZER EQ 250MG BASE/VIAL N60586 001
+ EQ 500MG BASE/VIAL N60586 002
@ EQ 250MG BASE/VIAL N60586 001
@ EQ 500MG BASE/VIAL N60586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC
TERRAMYCIN W/ POLYMYXIN
+ PFIZER EQ 5MG BASE/GM; 10,000 UNITS/GM N61841 001
@ EQ 5MG BASE/GM; 10,000 UNITS/GM N61841 001

TABLET; VAGINAL
TERRAMYCIN-POLYMYXIN
+ PFIZER EQ 100MG BASE; 100,000 UNITS N61009 001
@ EQ 100MG BASE; 100,000 UNITS N61009 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL

>_DLT_>		SMITHKLINE BEECHAM	EQ 10MG BASE	N20885 001 OCT 09, 1998
>_DLT_>			EQ 20MG BASE	N20885 002 OCT 09, 1998
>_DLT_>			EQ 30MG BASE	N20885 003 OCT 09, 1998
>_DLT_>	+		EQ 40MG BASE	N20885 004 OCT 09, 1998
>_ADD_>	@		EQ 10MG BASE	N20885 001 OCT 09, 1998
>_ADD_>	@		EQ 20MG BASE	N20885 002 OCT 09, 1998
>_ADD_>	@		EQ 30MG BASE	N20885 003 OCT 09, 1998
>_ADD_>	@		EQ 40MG BASE	N20885 004 OCT 09, 1998

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR

+	SMITHKLINE BEECHAM	EQ 12.5MG BASE	N20936 001 FEB 16, 1999
+		EQ 25MG BASE	N20936 002 FEB 16, 1999

PEMOLINE

TABLET; ORAL
CYLERT

AB	ABBOTT	**37.5MG**	**N16832 002**
AB	+	**75MG**	**N16832 003**
		18.75MG	N16832 001
	+	37.5MG	N16832 002
	+	75MG	N16832 003
	+	18.75MG	N16832 001
	PEMOLINE		
AB	COPLEY PHARM	**37.5MG**	**N75030 001** JAN 29, 1999
AB		**75MG**	**N75030 002** JAN 29, 1999
AB	INVAMED	**37.5MG**	**N75286 002** JUN 30, 1999
AB		**75MG**	**N75286 003** JUN 30, 1999

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB	SIDMAK LABS NJ	**400MG**	**N74874 001** MAY 25, 1999
AB	TORPHARM	**400MG**	**N75191 001** JUN 09, 1999
	PENTOXIL		
AB	UPSHER SMITH	**400MG**	**N74962 001** MAR 31, 1999

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

	@ HUESCHEN	2MG	N20184 001 DEC 30, 1993
	@	4MG	N20184 002 DEC 30, 1993
	@	8MG	N20184 003 DEC 30, 1993
	@ SOLVAY	2MG	N20184 001 DEC 30, 1993
	@	4MG	N20184 002 DEC 30, 1993
	@	8MG	N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	MPG CHEMISTS	**35MG**	**N85914 001**
	@	35MG	N85914 001
AA	PVT FORM	**35MG**	**N85697 001**
	@	35MG	N85697 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
FASTIN

AA	+ SMITHKLINE BEECHAM	**30MG**	**N17352 001**
	@	30MG	N17352 001
	PHENTERMINE HCL		
AA	ECN	**30MG**	***N86945 001*** ***JUL 20, 1983***

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	+	EON	30MG	N86945 001	JUL 20, 1983

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

> DLT >	AP	STERIS	50MG/ML	N85434 001	
> ADD >		@	50MG/ML	N85434 001	

> ADD > PIOGLITAZONE HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > ACTOS

> ADD >		TAKEDA	EQ 15MG BASE	N21073 001	JUL 15, 1999
> ADD >			EQ 30MG BASE	N21073 002	JUL 15, 1999
> ADD >		+	EQ 45MG BASE	N21073 003	JUL 15, 1999

POLYETHYLENE GLYCOL 3350

POWDER FOR RECONSTITUTION; ORAL
MIRALAX

	+	BRAINTREE	17GM/SCOOPFUL	N20698 001	FEB 18, 1999

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		ALCON	10,000 UNITS/ML; EQ 1MG BASE/ML	N64211 001	APR 13, 1998
AT		FALCON PHARMS	10,000 UNITS/ML; EQ 1MG BASE/ML	N64211 001	APR 13, 1998

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MICRO-K

AB		KV PHARM	8MEQ	N18238 001	
AB		ROBINS AH	8MEQ	N18238 001	

MICRO-K 10

AB	+	KV PHARM	10MEQ	N18238 002	MAY 14, 1984
AB	*	ROBINS AH	10MEQ	N18238 002	MAY 14, 1984

GRANULE, FOR RECONSTITUTION ER; ORAL
MICRO-K LS

	@	KV PHARM	20MEQ/PACKET	N19561 003	AUG 26, 1988
	@	ROBINS AH	20MEQ/PACKET	N19561 003	AUG 26, 1988

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

> DLT >	AP	AM PHARM PARTNERS	3MEQ/ML	N80225 003	
> ADD >	+		3MEQ/ML	N80225 003	
> DLT >	AP	STERIS	2MEQ/ML	N86208 001	
> DLT >	AP		2MEQ/ML	N89163 001	MAR 10, 1988
> DLT >	AP		2MEQ/ML	N89421 001	JAN 02, 1987
> DLT >	AP	*	3MEQ/ML	N86210 001	
> ADD >		@	2MEQ/ML	N86208 001	
> ADD >		@	2MEQ/ML	N89163 001	MAR 10, 1988
> ADD >		@	2MEQ/ML	N89421 001	JAN 02, 1987
> ADD >		@	3MEQ/ML	N86210 001	

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION
THAM-E

	+	ABBOTT	370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001	
	@		370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001	

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL
POTASSIUM CITRATE

	@ MISSION PHARMA	10MEQ/PACKET	N19647 002 OCT 13, 1988	> ADD > > DLT >	
	@	20MEQ/PACKET	N19647 001 OCT 13, 1988	> DLT > > DLT >	
	@ UNIV TX	10MEQ/PACKET	N19647 002 OCT 13, 1988	> ADD > > ADD >	
	@	20MEQ/PACKET	N19647 001 OCT 13, 1988		

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

AA	HALSEY	15MG/5ML	N40287 001 MAY 28, 1999		
AA	UDL	15MG/5ML	N40323 001 MAY 13, 1999		

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

> DLT >	+ STERIS	40MG/ML	N83767 001	> DLT >	
> ADD >	@	40MG/ML	N83767 001	> DLT >	

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED PLUS

AB	ALCON	1%	N17469 001	> ADD > > ADD >	
AB	FALCON PHARMS	1%	N17469 001	> ADD > > DLT >	
				> DLT > > ADD >	
				> ADD > > ADD >	

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL

	+ MERCK	EQ 20MG PHOSPHATE/ML	N11583 002		
	@	EQ 20MG PHOSPHATE/ML	N11583 002		

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
HYDELTRA-TBA

> DLT >	BP + MERCK	20MG/ML	N10562 001	> DLT > > DLT >	
	+ MERCK	20MG/ML	N10562 001	> ADD > > DLT >	
BP	STERIS	20MG/ML	N83362 001 FEB 17, 1984	> DLT > > DLT >	
	@	20MG/ML	N83362 001 FEB 17, 1984	> ADD > > ADD >	

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
HYDELTRA-TBA

	+ MERCK	20MG/ML	N10562 001	> ADD > > DLT >	
BP	STERIS	20MG/ML	N83362 001 FEB 17, 1984	> DLT > > DLT >	
	@	20MG/ML	N83362 001 FEB 17, 1984	> ADD > > ADD >	

PROBENECID

TABLET; ORAL
BENEMID

AB	+ MERCK	500MG	N07898 004		
	@	500MG	N07898 004		
	PROBENECID				
AB	MYLAN	500MG	N84211 002		
AB	+	500MG	N84211 002		

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HCL

				> DLT >	AP SMITH AND NEPHEW 100MG/ML N88530 001 MAR 04, 1985
				> DLT >	AP 500MG/ML N88531 001 MAR 04, 1985
	@	100MG/ML	N88530 001 MAR 04, 1985	> ADD > > ADD >	
	@	500MG/ML	N88531 001 MAR 04, 1985	> ADD > > ADD >	
				> DLT > > DLT >	AP STERIS 100MG/ML N87079 001 AP 500MG/ML N87080 001
	@	100MG/ML	N87079 001	> ADD > > ADD >	
	@	500MG/ML	N87080 001		

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

				> DLT >	AP SMITH AND NEPHEW EQ 5MG BASE/ML N89251 001 DEC 04, 1986
	@	EQ 5MG BASE/ML	N89251 001 DEC 04, 1986	> ADD > > ADD >	

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

> DLT >	AP		STERIS	EQ 5MG BASE/ML	N89606 001 JUL 08, 1987
> DLT					
> ADD >		@		EQ 5MG BASE/ML	N89606 001 JUL 08, 1987
> ADD >					

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMAZINE HCL

> DLT >	AP		STERIS	50MG/ML	N84517 001
> DLT >				25MG/ML	N84510 001
> ADD >		@		25MG/ML	N84510 001
> ADD >		@		50MG/ML	N84517 001
		SPARINE			
> DLT >	AP	+	WYETH AYERST	50MG/ML	N10349 006
> ADD >		+		50MG/ML	N10349 006

PROPOFOL

INJECTABLE; INJECTION
DIPRIVAN

	AB	+	ZENECA	10MG/ML	N19627 002 JUN 11, 1996
		+		10MG/ML	N19627 002 JUN 11, 1996
		PROPOFOL			
	AB		GENSIA SICOR PHARMS	10MG/ML	N75102 001 JAN 04, 1999

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
INDERAL

> DLT >	AP	+	WYETH AYERST	1MG/ML	N16419 001
> ADD >		+		1MG/ML	N16419 001
> DLT >		PROPRANOLOL HCL			
> DLT >	AP		SMITH AND NEPHEW	1MG/ML	N70137 001 APR 15, 1986
> DLT >					
> ADD >		@		1MG/ML	N70137 001 APR 15, 1986
> ADD >					

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB		GRANUTEC PHARMS	EQ 150MG BASE	N74488 001 JUL 31, 1997
AB			EQ 300MG BASE	N74488 002 JUL 31, 1997
AB		NOVOPHARM NC	EQ 150MG BASE	N74488 001 JUL 31, 1997
AB			EQ 300MG BASE	N74488 002 JUL 31, 1997
AB		PAR PHARM	EQ 150MG BASE	N75180 001 JAN 28, 1999
AB			EQ 300MG BASE	N75180 002 JAN 28, 1999

RISPERIDONE

TABLET; ORAL
RISPERDAL

	JANSSEN	0.25MG	N20272 008 MAY 10, 1999
+		0.5MG	N20272 007 JAN 27, 1999

RITONAVIR

CAPSULE; ORAL
NORVIR

	ABBOTT	100MG	N20945 001 JUN 29, 1999

SOLUTION; ORAL
NORVIR

	ABBOTT	80MG/ML	N20659 001 MAR 01, 1996
+		80MG/ML	N20659 001 MAR 01, 1996

ROFECOXIB

SUSPENSION; ORAL
VIOXX

MERCK	12.5MG/5ML	N21052 001 MAY 20, 1999

ROFECOXIB

SUSPENSION; ORAL
VIOXX
+ MERCK — 25MG/5ML — N21052 002 MAY 20, 1999

TABLET; ORAL
VIOXX
MERCK — 12.5MG — N21042 001 MAY 20, 1999
+ — 25MG — N21042 002 MAY 20, 1999

ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDIA
SMITHKLINE BEECHAM — EQ 2MG BASE — N21071 002 MAY 25, 1999
EQ 4MG BASE — N21071 003 MAY 25, 1999
+ — EQ 8MG BASE — N21071 004 MAY 25, 1999

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
+ HLR — 200MG — N20828 001 NOV 07, 1997
+ ROCHE — 200MG — N20828 001 NOV 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE
+ HLR — EQ 200MG BASE — N20628 001 DEC 06, 1995
+ ROCHE — EQ 200MG BASE — N20628 001 DEC 06, 1995

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
ELDEPRYL
@ SOMERSET — 5MG — N19334 001 JUN 05, 1989

SELEGILINE HCL
AB + SOMERSET — 5MG — N19334 001 JUN 05, 1989

SILVER SULFADIAZINE

CREAM; TOPICAL
THERMAZENE
> ADD > > ADD > > DLT > > DLT >
AB KENDALL LP — 1% — N18810 001 DEC 23, 1985
AB SHERWOOD MEDCL — 1% — N18810 001 DEC 23, 1985

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 10%
AP + FRESENIUS KABI — 10% — N17643 001
AP + PHARMACIA AND UPJOHN — 10% — N17643 001
INTRALIPID 20%
AP + FRESENIUS KABI — 20% — N18449 001
AP + PHARMACIA AND UPJOHN — 20% — N18449 001
INTRALIPID 30%
AP + FRESENIUS KABI — 30% — N19942 001 DEC 30, 1993
AP + PHARMACIA AND UPJOHN — 30% — N19942 001 DEC 30, 1993

SPIRONOLACTONE

TABLET; ORAL
ALDACTONE
> ADD > > ADD > > ADD > > ADD > > DLT > > DLT > > DLT > > DLT >
AB SEARLE — 50MG — N12151 008 DEC 30, 1982
AB + — 100MG — N12151 010 DEC 30, 1983
50MG — N12151 008 DEC 30, 1982
+ — 100MG — N12151 010 DEC 30, 1983

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE

	AB	PUREPAC PHARM	25MG	N87998 001 OCT 14, 1983
> ADD >	AB		50MG	N40353 001 JUL 29, 1999
> ADD >	AB		100MG	N40353 002 JUL 29, 1999
> ADD >	@		25MG	N87998 001 OCT 14, 1983

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SODIUM SULFACETAMIDE

AT	AKORN	10%	N83021 001
AT		15%	N83021 002
AT		30%	N83021 003
@		10%	N83021 001
@		15%	N83021 002
@		30%	N83021 003

SULFACETAMIDE SODIUM

AT	AKORN	10%	N40215 001 MAY 25, 1999
AT		30%	N40216 001 MAY 25, 1999

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

> DLT >	AP	STERIS	80MG/ML;16MG/ML	N71556 001 DEC 29, 1987
> ADD >	@		80MG/ML;16MG/ML	N71556 001 DEC 29, 1987

TACROLIMUS

CAPSULE; ORAL
PROGRAF

+	FUJISAWA HLTHCARE	EQ 1MG BASE	N50708 001 APR 08, 1994
		EQ 0.5MG BASE	N50708 003 AUG 24, 1998

TACROLIMUS

CAPSULE; ORAL
PROGRAF

	FUJISAWA HLTHCARE	EQ 1MG BASE	N50708 001 APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
A-N STANNOUS AGGREGATED ALBUMIN

@	NORTH AM CHEMS	N/A	N17916 001
@	SYNCOR PHARMS	N/A	N17916 001

PULMOLITE

BS	CIS	N/A	N17776 001
BS	DUPONT PHARMS	N/A	N17776 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION
MICROLITE

	CIS	N/A	N18263 001 MAR 25, 1983
	DUPONT PHARMS	N/A	N18263 001 MAR 25, 1983

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE

	CIS	N/A	N18467 001 MAR 16, 1982
	DUPONT PHARMS	N/A	N18467 001 MAR 16, 1982

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
OSTEOLITE

AP	CIS	N/A	N17972 001
AP	DUPONT PHARMS	N/A	N17972 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION
PYROLITE

		CIS	N/A	N17684 001
		DUPONT PHARMS	N/A	N17684 001

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE

AP	+	NOVARTIS	1MG/ML	N18571 001
	+		1MG/ML	N18571 001

BRICANYL

AP	+	HOECHST MARION RSSL	1MG/ML	N17466 001
	@		1MG/ML	N17466 001

TABLET; ORAL
BRETHINE

BP		NOVARTIS	2.5MG	N17849 001
BP	+		5MG	N17849 002
			2.5MG	N17849 001
	+		5MG	N17849 002

BRICANYL

BP		HOECHST MARION RSSL	2.5MG	N17618 001
BP			5MG	N17618 002
	@		2.5MG	N17618 001
	@		5MG	N17618 002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION
PARATHAR

	+	RHONE POULENC RORER	200 UNITS/VIAL	N19498 001 DEC 23, 1987
	@		200 UNITS/VIAL	N19498 001 DEC 23, 1987

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

> DLT >		STERIS	100MG/ML	N85599 001
> ADD >	@		100MG/ML	N85599 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

AB		PUREPAC PHARM	250MG	N60290 001
AB			500MG	N60290 002
	@		250MG	N60290 001
	@		500MG	N60290 002

TETRACYN

AB		PFIPHARMECS	250MG	N60082 003
AB			500MG	N60082 004
	@		250MG	N60082 003
	@		500MG	N60082 004

THEOPHYLLINE

INJECTABLE; INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	40MG/100ML	N19083 001	NOV 07, 1984
@ MCGAW	40MG/100ML	N19083 001	NOV 07, 1984

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	80MG/100ML	N19083 002	NOV 07, 1984
@ MCGAW	80MG/100ML	N19083 002	NOV 07, 1984

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	160MG/100ML	N19083 003	NOV 07, 1984
@ MCGAW	160MG/100ML	N19083 003	NOV 07, 1984

TABLET, EXTENDED RELEASE; ORAL
SUSTAIRE

BC		ROERIG	100MG	N85665 001
BC			300MG	N85665 002
	@		100MG	N85665 001
	@		300MG	N85665 002

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

AA		ALPHARMA	EQ 5MG BASE/ML	N70969 001 OCT 16, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL
@ ALPHARMA — EQ 5MG BASE/ML — N70969 001 OCT 16, 1987

TIAGABINE HYDROCHLORIDE

TABLET; ORAL
GABITRIL
+ ABBOTT — 2MG — N20646 005 APR 16, 1999

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID
> DLT > + — 250MG — N19979 002 OCT 31, 1991
> DLT > @ ROCHE — 125MG — N19979 001 MAR 24, 1993
> ADD > AB + SYNTEX — 250MG — N19979 002 OCT 31, 1991
> ADD > @ — 125MG — N19979 001 MAR 24, 1993
> ADD > TICLOPIDINE HCL
> ADD > AB TORPHARM — 250MG — N75089 001 JUL 01, 1999
> ADD >

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOLOL MALEATE
AB ALCON — EQ 0.25% BASE — N20963 001 OCT 21, 1998
AB — EQ 0.5% BASE — N20963 002 OCT 21, 1998
AB FALCON PHARMS — EQ 0.25% BASE — N20963 001 OCT 21, 1998
AB — EQ 0.5% BASE — N20963 002 OCT 21, 1998

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE
AT ADV REMEDIES — EQ 0.5% BASE — N74466 001 MAR 25, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE
AT AKORN — EQ 0.5% BASE — N74466 001 MAR 25, 1997
AT ALCON — EQ 0.25% BASE — N74261 001 APR 28, 1995
AT — EQ 0.5% BASE — N74262 001 APR 28, 1995
@ FALCON PHARMS — EQ 0.25% BASE — N74261 001 APR 28, 1995
@ — EQ 0.5% BASE — N74262 001 APR 28, 1995

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBREX
AT + ALCON — 0.3% — N50541 001
AT + FALCON PHARMS — 0.3% — N50541 001

TRETINOIN

SOLUTION; TOPICAL
TRETINOIN
AT MORTON GROVE — 0.05% — N75260 001 JAN 25, 1999

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
ARISTOCORT
AT FUJISAWA HLTHCARE — 0.025% — N83017 003
AT — 0.1% — N83016 004
AT — 0.5% — N83015 002
AT LEDERLE — 0.025% — N83017 003
AT — 0.1% — N83016 004
AT — 0.5% — N83015 002
ARISTOCORT A
AT FUJISAWA HLTHCARE — 0.025% — N83017 004
AT — 0.025% — N88818 001 OCT 16, 1984
AT — 0.1% — N83016 005
AT — 0.1% — N88819 001 OCT 16, 1984

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	ARISTOCORT A				
AT	FUJISAWA HLTHCARE	0.5%	N83015 003	> DLT >	
AT		0.5%	N88820 001	> DLT >	
			OCT 16, 1984	> ADD >	
AT	LEDERLE	0.025%	N83017 004	> ADD >	
AT		0.025%	N88818 001		
			OCT 16, 1984		
AT		0.1%	N83016 005		
AT		0.1%	N88819 001		
			OCT 16, 1984		
AT		0.5%	N83015 003		
AT		0.5%	N88820 001		
			OCT 16, 1984		

GEL; TOPICAL

ARISTOGEL			
@	FUJISAWA HLTHCARE	0.1%	N83380 001
@	LEDERLE	0.1%	N83380 001

OINTMENT; TOPICAL

	ARISTOCORT				
AT	FUJISAWA HLTHCARE	0.1%	N80750 004		
AT		0.5%	N80745 002	> DLT >	
AT	LEDERLE	0.1%	N80750 004	> DLT >	
AT		0.5%	N80745 002	> ADD >	
				> ADD >	
	ARISTOCORT A				
AT	FUJISAWA HLTHCARE	0.1%	N80750 003		
AT +		0.5%	N80745 003		
@		0.5%	N88781 001		
			OCT 05, 1984		
AT	LEDERLE	0.1%	N80750 003		
AT +		0.5%	N80745 003		
@		0.5%	N88781 001		
			OCT 05, 1984		

TRIAMCINOLONE DIACETATE

SYRUP; ORAL

ARISTOCORT		
FUJISAWA HLTHCARE	2MG/5ML	N11960 004
LEDERLE	2MG/5ML	N11960 004

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	TRIMETHOBENZAMIDE HCL				
AP	SMITH AND NEPHEW	100MG/ML	N88960 001		
			APR 04, 1986		
@		100MG/ML	N88960 001		
			APR 04, 1986		

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL

SULFA-TRIPLE #2			
AB +	GLOBAL PHARM	167MG;167MG;167MG	N80079 001
@		167MG;167MG;167MG	N80079 001
TRIPLE SULFOID			
AB	PAL PAK	167MG;167MG;167MG	N80094 001
+		167MG;167MG;167MG	N80094 001

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	TROPICAMIDE				
AT	STERIS	0.5%	N89171 001		
			DEC 28, 1990		
@		0.5%	N89171 001		
			DEC 28, 1990		

UREA, C-13

POWDER FOR RECONSTITUTION; ORAL

PYLORI-CHEK BREATH TEST			
+	ALIMENTERICS	100MG/VIAL	N20900 001
			FEB 04, 1999

VALRUBICIN

SOLUTION;

VALSTAR PRESERVATIVE FREE			
+	ANTHRA	40MG/ML	N20892 001
			SEP 25, 1998

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE			
+	ANTHRA	40MG/ML	N20892 001
			SEP 25, 1998

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		VERAPAMIL HCL				
AB		MYLAN	120MG	N75138 001	> ADD >	APR 20, 1999 > ADD
AB			180MG	N75138 002	> ADD >	APR 20, 1999 > ADD >
AB			240MG	N75138 003	> ADD >	APR 20, 1999 > ADD >
		VERELAN			> ADD >	
	+	ELAN	120MG	N19614 001	> ADD >	MAY 29, 1990 > ADD >
	+		180MG	N19614 003	> ADD >	JAN 09, 1992 > ADD >
	+		240MG	N19614 002	> ADD >	MAY 29, 1990 > ADD >
AB	+	ELAN PHARM	120MG	N19614 001	> ADD >	MAY 29, 1990 > ADD >
AB	+		180MG	N19614 003	> ADD >	JAN 09, 1992 > ADD >
AB	+		240MG	N19614 002	> ADD >	MAY 29, 1990 > ADD >

INJECTABLE; INJECTION

		VERAPAMIL HCL				
> DLT >	AP	SMITH AND NEPHEW	2.5MG/ML	N70696 001	> ADD >	JUL 31, 1987 > ADD >
> DLT >						
> ADD >		@	2.5MG/ML	N70696 001	> ADD >	JUL 31, 1987 > ADD >
> ADD >						

TABLET, EXTENDED RELEASE; ORAL

		VERAPAMIL HCL				
AB		DURAMED	120MG	N75072 001		MAY 25, 1999
AB			240MG	N75072 003		MAY 25, 1999

WARFARIN SODIUM

TABLET; ORAL

		COUMADIN				
AB	+	DUPONT MERCK	2MG	N09218 013		
AB			2MG	N09218 013		
AB			2.5MG	N09218 018		
AB	+		2.5MG	N09218 018		
AB			5MG	N09218 007		
AB	+		5MG	N09218 007		

WARFARIN SODIUM

TABLET; ORAL

		WARFARIN SODIUM				
AB		TARO	1MG	N40301 002		JUL 15, 1999
AB			2MG	N40301 003		JUL 15, 1999
AB			2.5MG	N40301 004		JUL 15, 1999
AB			3MG	N40301 005		JUL 15, 1999
AB			4MG	N40301 006		JUL 15, 1999
AB			5MG	N40301 007		JUL 15, 1999
AB			6MG	N40301 008		JUL 15, 1999
AB			7.5MG	N40301 009		JUL 15, 1999
AB			10MG	N40301 001		JUL 15, 1999

ZANAMIVIR

CAPSULE; INHALATION

		RELENZA				
	+	GLAXO WELLCOME	5MG	N21036 001		JUL 26, 1999

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN				
+ G AND W LABS	120MG	N18060 001	> ADD >	
+	325MG	N18060 003	> ADD >	
		DEC 18, 1986		
+	650MG	N18060 002		
	120MG	N18060 001		
	325MG	N18060 003	> ADD >	
		DEC 18, 1986	> ADD >	
	650MG	N18060 002		
ACETAMINOPHEN				
ASCENT PEDS	120MG	N18337 003		
		SEP 12, 1983		
	325MG	N18337 002		
+	650MG	N18337 001		
UPSHER SMITH	120MG	N18337 003		
		SEP 12, 1983		
	325MG	N18337 002		
	650MG	N18337 001		
INFANTS' FEVERALL				
ASCENT PEDS	80MG	N18337 004		
		AUG 26, 1992		
UPSHER SMITH	80MG	N18337 004		
		AUG 26, 1992		

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC		
+ SMITHKLINE	8MG;75MG	N18099 001
@	8MG;75MG	N18099 001
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE		
CENT PHARMS	8MG;75MG	N18809 001
		MAY 07, 1984
+	8MG;75MG	N18809 001
		MAY 07, 1984

TABLET, EXTENDED RELEASE; ORAL

CONTAC		
NOVARTIS	12MG;75MG	N19613 001
		JUN 13, 1986
+	12MG;75MG	N19613 001
		JUN 13, 1986
TRIAMINIC-12		
+ NOVARTIS	12MG;75MG	N18115 001
@	12MG;75MG	N18115 001

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200		
+ SMITHKLINE BEECHAM	200MG/20ML	N20951 001
		JUL 09, 1999

TABLET; ORAL

CIMETIDINE		
DANBURY PHARMA	200MG	N75425 001
		JUL 29, 1999
ZENITH GOLDLINE	200MG	N75345 001
		JUN 16, 1999

CLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN AF		
SCHERING PLOUGH	1%	N17619 002
		OCT 27, 1989

LOTION; TOPICAL

LOTRIMIN AF		
SCHERING	1%	N18813 002
		OCT 27, 1989

SOLUTION; TOPICAL

LOTRIMIN AF		
SCHERING PLOUGH	1%	N17613 002
		OCT 27, 1989

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER-EPI		
+ 3M	0.3MG/INH	N10374 003
@	0.3MG/INH	N10374 003

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN		
ALPHARMA	100MG/5ML	N74916 001
		APR 30, 1999

IBUPROFEN

TABLET; ORAL
IBUPROFEN

LNK	200MG	N75010 001 MAR 01, 1999	
	200MG	N75139 001 MAR 01, 1999	
NORTON HN	200MG	N71144 001 JAN 20, 1987	
	200MG	N72901 001 DEC 19, 1991	
	200MG	N72903 001 DEC 19, 1991	> ADD >
ZENITH GOLDLINE	200MG	N71144 001 JAN 20, 1987	> ADD >
	200MG	N72901 001 DEC 19, 1991	> ADD >
	200MG	N72903 001 DEC 19, 1991	

JUNIOR STRENGTH IBUPROFEN

PERRIGO	100MG	N75367 001 APR 22, 1999

IBUPROFEN POTASSIUM

CAPSULE; ORAL
PROVEL

+ NOVARTIS	200MG	N20402 001 APR 20, 1995	
+ WHITEHALL ROBINS	200MG	N20402 001 APR 20, 1995	

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 3 COMBINATION PACK

ALPHARMA US PHARM	2%,200MG	N74926 001 APR 16, 1999

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO	2%,200MG	N75329 001 APR 20, 1999

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

ALPHARMA US PHARM	100MG	N73507 001 NOV 19, 1993

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

NMC	100MG	N73507 001 NOV 19, 1993

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)

PERRIGO	2%	N75357 001 JUL 30, 1999

MINOXIDIL (FOR WOMEN)

PERRIGO	2%	N75357 002 JUL 30, 1999

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP

+ ELAN PHARM	11MG/24HR	N19983 003 DEC 23, 1998
+	22MG/24HR	N19983 004 DEC 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICOTINE POLACRILEX

CIRCA	EQ 2MG BASE	N74507 001 MAR 15, 1999
	EQ 4MG BASE	N74707 001 MAR 19, 1999

NONOXYNOL-9

SPONGE; VAGINAL
TODAY

@ ALLENDALE PHARMS	1GM	N18683 001 APR 01, 1983
@ WHITEHALL ROBINS	1GM	N18683 001 APR 01, 1983

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL			
PSEUDOEPHEDRINE HCL			
PERRIGO	120MG		N75153 001 FEB 26, 1999

RANITIDINE HYDROCHLORIDE

TABLET; ORAL			
RANITIDINE HCL			
NOVOPHARM	EQ 75MG BASE		N75094 001 JUN 21, 1999
RANBAXY	EQ 75MG BASE		N75132 001
ZANTAC 75			
+ GLAXO WELLCOME	EQ 75MG BASE		N20520 001 DEC 19, 1995
+ WARNER LAMBERT	EQ 75MG BASE		N20520 001 DEC 19, 1995

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL			
LAMISIL			
+ NOVARTIS	1%		N20980 001 MAR 09, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 7 JUL '99

NO JULY 1999 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
111Indium pentetreotide TN= SomatoTher	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation 1600 Canal St. 10th Floor New Orleans, LA 70112 DD=06/10/1999
166Ho-DOTMP TN=	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Seattle, WA 98119 DD=02/10/1999
6-hydroxymethylacylfulvene TN=	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. Suite 300E, Opus Center 9900 Bren Road East Minnetonka, MN 55343 DD=04/06/1999
6-hydroxymethylacylfulvene TN=	Treatment of ovarian cancer.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E, Opus Center Minnetonka, MN 55343 DD=07/06/1999
6-hydroxymethylacylfulvene TN=	Treatment of renal cell carcinoma.	MGI Pharma, Inc. 9900 Bren Road East Suite 300 E, Opus Center Minnetonka, MN 55343 DD=07/27/1999

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Alitretinoin TN= Panretin	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998 MA=02/02/1999
Amifostine TN= Ethyol	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998 MA=06/24/1999
Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized TN= Humate-P	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric patients.	Centeon Pharma GmbH Emil-von-Behring-Strasse 76 35041 Marburg Germany DD=10/16/1992 MA=04/01/1999
Artesunate TN=	Treatment of malaria.	World Health Organisation Special Programme for Research and Training in Tropical Diseases Via Appia Geneva 27, Switzerland, DD=07/19/1999

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Atovaquone TN= Mepron	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709 DD=08/14/1991 MA=01/05/1999
Autologous DNP-conjugated tumor vaccine TN= M-Vax	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 4520 Main St. Suite 930 Kansas City, MO 64111 DD=02/23/1999
Beraprost TN=	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box 14186 Research Triangle Park, NC 27709 DD=04/29/1999
Bexarotene TN= Targretin	Treatment of cutaneous T-cell lymphoma.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. San Diego, CA 92121 DD=06/18/1999
Bleomycin TN= Blenoxane	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego, CA 92121 DD=02/09/1999

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Busulfan TN= Busulfex	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=07/28/1994 MA=02/04/1999
CT-2584 mesylate TN=	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle, WA 98119 DD=04/16/1999
CT-2584 mesylate TN=	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Seattle, WA 98119 DD=04/16/1999
Coagulation factor VIIa (recombinant) TN= NovoSeven	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, Inc. 100 Overlook Center Suite 200 Princeton, NJ 08540 DD=06/06/1988 MA=03/25/1999
Cytarabine liposomal TN= DepoCyt	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego, CA 92121 DD=06/02/1993 MA=04/01/1999
Decitabine TN=	Treatment of myelodysplastic syndromes.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Decitabine TN=	Treatment of chronic myelogenous leukemia.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999
Denileukin diftitox TN= Ontak	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/1996 MA=02/05/1999
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View, CA 94039 DD=11/04/1998 MA=06/28/1999
Epoprostenol TN= Flolan	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Glaxo Wellcome Inc. Five Moore Dr. PO Box 13398 Research Triangle Park, NC 27709 DD=03/22/1999
Etanercept TN= Enbrel	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=10/27/1998 MA=05/27/1999

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Etanercept TN= Enbrel	Treatment of Wegener's granulomatosis.	Stone, MD, MPH, John H. Johns Hopkins Vasculitis Center, Division of Rheumatology 1830 East Monument St., Suite 7500 Baltimore, MD 21205 DD=04/06/1999
Fluoxetine TN= Prozac	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Dept. of Psychiatry Box 1230, One Gustave L. Levy Place New York, NY 10029 DD=04/30/1999
Humanized MAb (IDEC-131) to CD40L TN=	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego, CA 92121 DD=02/09/1999
Interferon beta-1a (recombinant human) TN= Avonex	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=01/07/1999
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B) TN= 131IchTNT-1	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Techniclone Corporation 14282 Franklin Ave. Tustin, CA 92780 DD=02/12/1999

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Japanese encephalitis vaccine (live, attenuated) TN=	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul 121-010 South Korea, DD=05/19/1999
L-5-hydroxytryptophan TN=	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc. 311 Bonnie Circle P.O. Box 1900 Corona, CA 91718 DD=01/20/1999
Lactic acid TN= Aphthaid	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale Conklin Hall Farmingdale, NY 11735 DD=06/29/1999
Lidocaine patch 5% TN= Lidoderm Patch	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Hind Health Care, Inc. 3707 Williams Rd., Suite 101 San Jose, CA 95117 DD=10/24/1995 MA=03/19/1999
Lisofylline TN=	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Ave. W., Suite 400 Seattle, WA 98119 DD=06/10/1999
Marijuana TN=	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc. 3 Francis St. Belmont, MA 02478 DD=05/25/1999

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Murine MAb to polymorphic epithelial mucin, human milk fat globule 1 TN= Theragyn	Adjuvant treatment of ovarian cancer.	Antisoma West Africa House Hanger Lane London W5 3QR, UK DD=03/22/1999
N-acetylgalactosamine-4-sulfatase, recombinant human TN=	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato, CA 94949 DD=02/17/1999
Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine TN= MEDI-491	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=05/07/1999
Pegylated arginine deiminase TN= Hepacid	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=03/26/1999
Pegylated arginine deiminase TN= Melanocid	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=04/12/1999
Recombinant human C1-esterase inhibitor TN=	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human C1-esterase inhibitor TN=	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999
Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3 TN=	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Dr. Santa Clara, CA 95054 DD=06/15/1999
Recombinant human nerve growth factor TN=	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=04/16/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Rifalazil TN=	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=04/13/1999

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
SCH 58500 TN=	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=04/12/1999
Sodium 1,3-propanedisulfonate TN=	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite 100 Saint-Laurent, Quebec Canada H4S 2A1 DD=04/06/1999
Sodium dichloroacetate TN= Ceresine	Treatment of severe head injury.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=06/14/1999
Somatropin [rDNA] TN= Genotropin	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn 7000 Portage Rd. 0633-298-113 Kalamazoo, MI 49001 DD=07/06/1999
Synthetic human secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999

Orphan Product Designations and Approvals List
July 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Synthetic porcine secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Thalidomide TN= Thalomid	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=04/06/1999
Tobramycin TN= Tobi	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=06/18/1999
Transgenic human alpha 1 antitrypsin TN=	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K. DD=05/19/1999

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 1999 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 19TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NP* **NEW PRODUCT (MINT FLAVORED)**

REFERENCES

NEW DOSING SCHEDULE

D-50 **INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS**

NEW INDICATION

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER

I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES

I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

PATENT USE CODE

U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.
U-265	USE AS A LAXATIVE
U-266	OSTEOARTHRITIS
U-267	METHOD FOR PREVENTING HEARTBURN
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020482 004	ACARBOSE;PRECOSE				I-252	SEP 29, 2001
						I-253	SEP 29, 2001
>ADD>	020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
>ADD>			RE34440	MAR 31, 2010	U-275		
>ADD>	020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
>ADD>			RE34440	MAY 31, 2010	U-275		
	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA				I-262	JUN 02, 2002
>ADD>	019621 001	ALBUTEROL SULFATE;VENTOLIN	4594359	JUN 10, 2003			
	020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
						NCE	FEB 02, 2004
	020221 001	AMIFOSTINE;ETHYOL				ODE	JUN 24, 2006
	021007 001	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021007 002	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
	020500 001	ATOVAQUONE;MEPRON				ODE	JAN 05, 2006
						I-255	JAN 05, 2002
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
			5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
	020313 002	CALCITONIN, SALMON;MIACALCIN	5759565	JUN 02, 2015			
>ADD>	020896 001	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
>ADD>			4966891	NOV 08, 2008	U-272		
>ADD>	020896 002	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
>ADD>			4966891	NOV 08, 2008	U-272		
>ADD>	020712 001	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
>ADD>	020712 002	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
	020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NS	MAY 24, 2002
			5177080	NOV 26, 2011			
	020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010			
	020863 001	CILOSTAZOL;PLETAL	4277479	AUG 29, 1999		NCE	JAN 15, 2004
	020863 002	CILOSTAZOL;PLETAL	4277479	AUG 29, 1999		NCE	JAN 15, 2004
>ADD>	019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
>ADD>			5286754	FEB 15, 2011			
	020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	5648093	JUL 15, 2014			
	021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
						NP	APR 01, 2002
	020287 001	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 003	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 004	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	017922 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 003	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 002	DESMOPRESSIN ACETATE;DDAVP				PC	DEC 19, 1999
	074752 001	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 19, 1999
	074752 003	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 19, 1999
	074752 004	DILTIAZEM HYDROCHLORIDE;CARTIA XT					
	020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010			
			5438072	NOV 22, 2013			
			5698582	JUL 03, 2012			
			5714512	JUL 03, 2012			
			5602116	APR 03, 2115	U-278	NCE	JUN 09, 2004
>ADD>	020862 001	DOXERCALCIFEROL;HECTOROL	5707980	FEB 11, 2117	U-278		
>ADD>						ODE	JUN 28, 2006
	050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL	5811423	AUG 07, 2012	U-256		
	020972 001	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
			5811423	AUG 07, 2012	U-256		
	020972 002	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
			5519021	MAY 21, 2013			
	020972 003	EFAVIRENZ;SUSTIVA	5663169	SEP 02, 2014	U-257		
			5811423	AUG 07, 2012	U-256		
	020375 001	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 002	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 003	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
	020908 001	ESTRADIOL;VAGIFEM				NP	MAR 26, 2002
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	020527 003	ESTROGENS, CONJUGATED;PREMPRO 14/14	4826831	MAY 02, 2006			
			5547948	JAN 17, 2015			
	020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020325 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-267		
	020801 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-267		
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	020747 001	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 002	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 003	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 004	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 005	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 006	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020955 001	FERRIC SODIUM GLUCONATE;FERRLECIT				NCE	FEB 18, 2004
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5855912	FEB 28, 2015			
			5738872	FEB 28, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020788 001	FINASTERIDE;PROPECIA	5571817	NOV 05, 2013	U-259		
			5886184	NOV 19, 2012			
	020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	U-262		
			5886184	NOV 19, 2012			
			4377584	MAR 22, 2000	U-261		
>ADD>	019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-265	AUG 18, 2002
	020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
			4626549	DEC 02, 2003			
	020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
			4626549	DEC 02, 2003			
>ADD>	019958 001	FLUTICASONE PROPIONATE;CUTIVATE				I-267	JUN 17, 2002
	020121 001	FLUTICASONE PROPIONATE;FLONASE				I-258	DEC 11, 2001
	020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
	020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
>ADD>	021057 001	GANIRELIX ACETATE;ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
>ADD>			5767082	JUN 16, 2015			
>ADD>	020305 001	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
>ADD>	020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
	020491 001	IBUTILIDE FUMARATE;CORVERT				D-50	MAY 13, 2002
	020083 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020657 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
			4267179	JUN 23, 2000			
>ADD>	021066 001	KETOTIFEN FUMARATE;ZADITOR				NCE	JUL 02, 2004
	020564 001	LAMIVUDINE;EPIVIR	5905082	MAY 18, 2016			
	020564 002	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
			5905082	MAY 18, 2016			
	020596 002	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
	020764 001	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 002	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 003	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U-260		
			5422368	MAR 22, 2011	U-260		
			4599353	JUL 28, 2006	U-260		
>ADD>	020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	4652441	NOV 01, 2004			
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
>ADD>	020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
>ADD>	020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
>ADD>	020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
>ADD>	021045 001	LEVONORGESTREL;PLAN B				NP	JUL 28, 2002
	019941 001	LIDOCAINE;EMLA				I-260	MAR 11, 2002
	020612 001	LIDOCAINE;LIDODERM				ODE	MAR 19, 2006
	019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 30, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
>ADD>	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
>ADD>	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
>ADD>	020969 001	METHOXSALEN;UVADEX	5036102	JUL 30, 2008	U-273	NP	FEB 25, 2002
>ADD>			4999375	MAR 12, 2008			
			4845075	APR 11, 2009			
>ADD>	020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5514698	MAR 21, 2014		NP	JUN 30, 2002
	020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020717 001	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
	020717 002	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
	018612 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020066 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
>ADD>	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5922338	JUL 13, 2016		ODE	NOV 25, 2005
>ADD>			5922682	JUL 13, 2016			
			5688530	NOV 18, 2014	U-268		
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
>ADD>	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5922338	JUL 13, 2016		ODE	NOV 25, 2005
>ADD>			5922682	JUL 13, 2016			
			5688530	NOV 18, 2014	U-268		
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
>ADD>	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5922338	JUL 13, 2016		ODE	NOV 25, 2005
>ADD>			5922682	JUL 13, 2016			
			5688530	NOV 18, 2014	U-268		
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
	020766 001	ORLISTAT;XENICAL				NCE	APR 23, 2004
	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		NP	DEC 16, 2001
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			5840754	MAY 22, 2015			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5912268	MAY 22, 2015			
	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		NP	DEC 16, 2001
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5912268	MAY 22, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		NP	DEC 16, 2001
>ADD>			5674895	MAY 22, 2015			
>ADD>			4783337	SEP 16, 2003			
>ADD>			5082668	SEP 16, 2003			
			5912268	MAY 22, 2015			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
	020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
>ADD>	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
>ADD>			4687777	JAN 17, 2006			
>ADD>	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
>ADD>			4687777	JAN 17, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
>ADD>			4687777	JAN 17, 2006			
	020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U-265	NP	FEB 18, 2002
>ADD>	019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015			
>ADD>			5714520*PED	SEP 22, 2015			
>ADD>			5731355	MAR 22, 2015	U-217		
>ADD>			5731355*PED	SEP 22, 2015	U-217		
>ADD>			5731356	MAR 22, 2015	U-218		
>ADD>			5731356*PED	SEP 22, 2015	U-218		
>ADD>			5908869	MAR 22, 2015	U-270		
>ADD>			5908869*PED	SEP 22, 2015	U-270		
	075102 001	PROPOFOL;PROPOFOL				PC	OCT 16, 1999
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
>ADD>	020973 001	RABEPRAZOLE SODIUM;ACIPHEX				NCE	AUG 19, 2004
>ADD>	020973 002	RABEPRAZOLE SODIUM;ACIPHEX				NCE	AUG 19, 2004
>ADD>	075094 001	RANITIDINE HYDROCHLORIDE;RANITIDINE HCL				PC	JAN 13, 2000
>ADD>	020984 001	RAPACURONIUM BROMIDE;RAPLON				NCE	AUG 18, 2004
>ADD>	020984 002	RAPACURONIUM BROMIDE;RAPLON				NCE	AUG 18, 2004
	020903 001	RIBAVIRIN;REBETOL	5914128	DEC 22, 2017			
>ADD>	020272 007	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
			4804663	DEC 29, 2007	U-90		
>ADD>	020272 008	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
			4804663	DEC 29, 2007	U-90		
>ADD>	020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
>ADD>	020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
>ADD>	021012 001	TECHNETIUM TC-99M DEPREOTIDE;TECHNETIUM TC99M DEPREOTIDE KIT				NCE	AUG 03, 2004
>ADD>	021029 001	TEMOZOLOMIDE;TEMODAL	5260291	NOV 09, 2010		NCE	AUG 11, 2004
>ADD>						ODE	AUG 11, 2006
>ADD>	021029 002	TEMOZOLOMIDE;TEMODAL	5260291	NOV 09, 2010		NCE	AUG 11, 2004
>ADD>						ODE	AUG 11, 2006
>ADD>	021029 003	TEMOZOLOMIDE;TEMODAL	5260291	NOV 09, 2010		NCE	AUG 11, 2004
>ADD>						ODE	AUG 11, 2006
>ADD>	021029 004	TEMOZOLOMIDE;TEMODAL	5260291	NOV 09, 2010		NCE	AUG 11, 2004
>ADD>						ODE	AUG 11, 2006
>ADD>	074823 001	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 08, 2000
>ADD>	074823 002	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 08, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	074823 003	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 08, 2000
>ADD>	074823 004	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 08, 2000
	020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-73	NCE	DEC 30, 1999
			4755534	DEC 30, 2006	U-73		
	020846 001	TERBINAFINE;LAMISIL				NCE	DEC 30, 1999
	019762 001	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	019762 002	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
			5354760	MAR 24, 2012			
	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
>ADD>	020505 001	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
>ADD>	020505 002	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
>ADD>	020505 003	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
>ADD>	020505 004	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
>ADD>	020505 005	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
>ADD>	020505 006	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
>ADD>	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				I-266	JUL 23, 2002
>ADD>	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				I-266	JUL 23, 2002
>ADD>	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				I-266	JUL 23, 2002
	020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN				I-256	NOV 30, 2001
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
	020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
>ADD>	020859 001	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
>ADD>	020859 002	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
>ADD>	021036 001	ZANAMIVIR;RELENZA	D379506	MAY 27, 2011		NCE	JUL 26, 2004
>ADD>			4778054	OCT 18, 2005			
>ADD>			4811731	JUL 29, 2006			
>ADD>			5035237	JUL 30, 2008			
>ADD>			5360817	NOV 01, 2011			
>ADD>			5648379	JUL 15, 2014	U-274		
>ADD>			4627432	DEC 09, 2003			